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In the past, cardiomyocytes were believed to be permanently withdrawn 
from the cell cycle shortly after the postnatal period and this "irreversible" cell cycle 
exit limits the capability of adult cardiac myocytes to proliferate again upon heart 
injury or chronic heart failure. For this reason, further response to growth, increased 
workload and injury is restricted to increase in cell mass of existing myocytes, i.e. 
hypertrophy. However, the dogma that the adult heart is a postmitotic organ has been 
challenged by the recent findings of the proliferating myocytes after myocardial 
infarction and the capacity of terminally differentiated cardiomyocytes to reenter cell 
cycle. Notwithstanding this controversy, the elucidation of the molecular switches 
that control the cardiac growth is now of the great interest for the therapeutic 
approach of heart regeneration. 
Among the ten major ingredients commonly found in the traditional Chinese 
formulations for treating coronary heart disease and heart failure, Radix 
Ophiopogonis (Mai Dong, MD) and Radix Astragali (Huang Qi, HQ) were found to 
induce DNA synthesis in both day 1 and day 7 neonatal primary rat cardiomyocytes. 
As rat cardiomyocytes switch from hyperplastic to hypertrophic growth between day 
3 and day 4 postnatal, MD and HQ may have the potential to modulate cardiac 
growth during development. To further confirm the mitogenic effect of MD and HQ, 
V 
Abstract 
BrdU assay on differentiated H9C2 cardiac cells after pretreatments of MD and HQ 
was performed. And, this mitogenic effect may possibly involve the induction of 
some intracellular signals, which may further modulate the differential gene 
expression that regulate the cell cycle or proliferation since pretreatments of H9C2 
cardiac cells with MD and HQ were found to have an increase of BrdU incorporation 
than that of the control ones. Thus, further experiments are currently in progress to 
investigate any differential gene expression in rats with and without drug treatment 
by using our subtracted cDNA microarray slides from the subtraction library clones 
between day 1 and day 7 SD rat hearts. Hopefully, in the foreseeable future, heart can 
be regenerated after injury just by turning on those critical genes which are once 
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Introduction 
Chapter 1 INTRODUCTION 
1,1 The Transition of Hyperplastic to Hypertrophic 
Growth During Heart Development 
During postnatal myocardial development, cardiomyocytes progressively cease 
to undergo mitosis and hyperplasia in human, rat and mouse (Soonpaa and Field, 
1998). Since rat cardiomyocytes lose their capacity to replicate after about two weeks, 
in particular, switch from hyperplastic to hypertrophic growth between days 3 and 4 
postnatal (Clubb and Bishop, 1984; Li et cd., 1996a), myocardial growth from this 
time is primarily due to hypertrophy of existing cardiomyocytes (Engelmann and 
Gerrity, 1988; Oparil et aL, 1984). This cessation of proliferation has been attributed 
to a block in cell cycle with myocytes locked either in the Go or Gi phases (Capasso 
et al., 1992; McGill and Brooks, 1995). Although numerous studies have indicated 
that in the course of differentiation, retinoblastoma protein (Rb) phosphorylation, 
cyclins as well as cyclin-dependent kinases (CDKs) activities are reduced in 
association with cell cycle arrest (Flink et al., 1998; Kang et al., 1997), the molecular 
mechanism that regulate the rapid transition from hyperplasia to hypertrophy in 
cardiomyocytes remains largely unknown. 
Basically, cyclins are classified either as Gi and S cyclins or G2 and M cyclins, 
depending on their role and on protein abundance during the cell cycle (Hunter and 
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Pines, 1994; Sherr, 1993). Usually, they regulate cell cycle progression in association 
with specific cyclin-dependent kinase(s) such as cyclin A，which is predominant in S 
and G2 phases, associates with CDK2 or cell division cycle 2 (cdc2) for the 
progression through the S and G2 phases while cyclin B, belonged to M phase cyclin, 
along with cdc2 regulate the entry of mitotic (M) phase (Lees, 1995; Morgan, 1995). 
In addition, cyclins availability and the phosphorylation state of specific serine or 
threonine residues of CDKs were also found to be the main regulator of the 
cyclin/CDK function (Morgan, 1995). 
Besides cyclins, CDKs, telomerase activities and Rb phosphorylation were 
found to regulate the rapid transition from hyperplasia to hypertrophy in myocardium, 
a sequence of master genes such as c-fos, c-myc (Claycomb et al., 1987), E2F (Vara 




1.2 The Controversial Capability of Heart Regeneration 
Unlike skeletal muscle cells, adult cardiomyocytes are generally considered as 
non-regenerative because they are terminally differentiated and cannot reenter the 
cell cycle as well as they lacks progenitors like satellite cells in skeletal muscle to 
generate new myocytes (Asakura et al, 2001; Snow, 1978; Zammit et al., 2002). 
Therefore, hypertrophy has been the main acknowledged form of compensatory 
myocyte growth in the adult heart upon pressure-volume overload or injury instead 
of hyperplasia (Chien, 1999; Engelmann and Gerrity, 1988; Oparil et al., 1984). 
Moreover, the dogma that adult cardiomyocytes are permanently withdrawn 
from the cell cycle soon after birth has been challenged by the observations that 
myocyte cellular hyperplasia does occur throughout life (Anversa and Kajstura, 1998) 
and the renewal rate increases significantly under a variety of pathological conditions 
in humans (Beltrami et al.’ 2001; Quaini et al” 1994) and animals (Olivetti et al, 
1987; Olivetti et al., 1992). Also, an increasing number of reports documented that 
stem-like primitive cells are present in the myocardium either as a resident 
population of embryonic origin or as a blood-bom population that continuously seeds 
the tissue (Beltrami et al.’ 2001; Orlic et al, 2001; Quaini et al., 2002). But whether 
this regenerative potential in adult cardiomyocytes can be clinically significant to 
reconstitute damaged cardiomyocytes and replenish the myocardial loss after heart 
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diseases or injury is still under debate (Anversa et al., 2003; Glaser et al., 2002). 
Regardless of this controversy, a better understanding on the genes that regulate 
cardiac growth and development may help to maximize the intrinsic proliferative 
capacity of adult cardiomyocytes. 
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1.3 Challenges in Treating Heart Diseases 
Heart diseases, being the second leading cause of deaths in Hong Kong over the 
last two decades, claimed more than 60,000 hospital admissions and 5,537 deaths in 
2000 (www.info.gov.hk/dh/diseases/ncd/eng/heart.htm). Although the age-
standardized mortality rates for heart diseases have declined thanks to the rapid 
advances in medical technology, recent report from the WHO warned that heart 
diseases were on the rise in developing countries, particularly in India and China. 
And these problems may also be persistent in our aging population as the incidence 
of heart diseases increases with age. 
Congestive heart failure, which is one of the most significant causes of 
morbidity and mortality worldwide, usually occurs as a late manifestation in diverse 
cardiovascular diseases characterized by the loss of contractile muscle mass and / or 
by volume or pressure overload. With the general belief of adult cardiomyocytes are 
terminally differentiated cells, it has been traditionally accepted that they are not able 
to regenerate once they cease to proliferate shortly after birth. For this reason, 
necrotized cardiomyocytes in infarcted ventricular tissues are progressively replaced 
by fibroblasts to form scar tissues and consequently heart failure and progressive 
contractile dysfunction will be resulted. 
However, recent findings of the proliferating myocytes after myocardial 
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infarction (Beltrami et al., 2001) and the capacity of terminally differentiated 
cardiomyocytes to reenter cell cycle (Engel et al.’ 1999) really do shed light on a new 
approach in treating heart diseases, based on the regeneration of adult myocardium. 
In this regard, identifying the genes and their underlying mechanism(s) that are able 
to promote cardiomyocyte proliferation might open new directions of strategies in 
treating cardiovascular diseases that cause cardiomyocyte loss. 
6 
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1.4 A New Insight Behind Traditional Chinese Medicine 
(TCM) for Treating Heart Diseases 
With the lack of a desirable drug therapy for curing heart diseases, over the past 
few years, flurries of attempts have been made in establishing a reliable cell therapy 
for treating heart diseases. Although many of the cell transplantation experiments 
reported improvement in cardiac function (Anversa and Nadal-Ginard, 2002; 
Ruiz-Cano et al., 2003), it has been difficult to demonstrate long-term benefit as well 
as integration and electrical coupling of the transplanted cells with the host 
myocardium (Menasche et al, 2001). For this reason, some scientists start to explore 
and develop new pharmacological agents that can modulate expression of the 
endogenous genes within the myocardium. 
Traditional Chinese Medicine (TCM), which was used by Chinese for at least 
2,000 years, with its long history and clinical experience may provide invaluable 
information for treating heart diseases. As TCM is a natural product with milder side 
effects, its potential use in curing heart diseases is being under investigated. However, 
up till now, the gene expression and their underlying mechanisms that are modulated 
by these effective TCM remain obscure. Therefore, in order to disclose the potential 
capability of TCM in promoting cardiomyocyte growth, in particular the regulation 
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on the rapid hyperplasia to hypertrophy switch in myocardial development, TCM 
which is able to induce mitogenic effect on cardiomyocytes will be as a potential 
target for further investigation on the gene expression that involved in cardiac 
development. 
Based on the expressed sequence tags (ESTs) sequencing and suppression 
subtractive hybridization, our colleagues had successfully identified over 200 
putative differentially expressed genes of the ventricular myocardium in day 1 and 
day 7 postnatal Sprague-Dawley (SD) rats recently (Chim et al” 2000a). Since day 3 
and day 4 postnatal are the critical point for rat cardiomyocytes to switch from 
hyperplastic to hypertrophic growth (Clubb and Bishop, 1984; Li et al., 1996a), 
many important factors involved in the molecular mechanism of the rat myocardial 
development especially during the hyperplasia to hypertrophy switch are reasonably 
contained in this pool of subtracted genes. For example, the mRNA expression of 
40-kDa subunit of replication factor C (RFC p40 or RFC2), which is an essential 
processive factor for proliferating cellular nuclear antigen-dependent DNA 
replication was found to be down-regulated during neonatal myocardial development 
(Chim et al., 2000b). 
Therefore by using cDNA microarray technique and our own subtracted cDNA 
microarray slides from the subtraction library clones between day 1 and day 7 SD rat 
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ventricular myocardium, we can have a better understanding of the change in gene 
expression profile and their underlying mechanisms that are modulated by those 
effective mitogenic TCMs on cardiomyocytes. Hopefully, in the foreseeable future, 
heart can be regenerated after injury by turning on those critical genes which are 
once turned off during the heart development. 
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1.5 The Potential Mitogenic TCMs on Cardiomyocytes 
In my study, TCM which was found to be the main component (i.e. over 40%) 
of the Traditional Chinese formulations appearing over 50% in those Chinese 
Medicine Books for treating heart diseases would be considered as our target TCM. 
And based on the above criteria, ten TCMs (Table 1) were found. 
Radix Ophiopogonis Radix Astragali 
麥冬 ^ 
Cortex Periplocae Radix Aconiti Lateralis Preparata 
香加皮 制附子 
Fructus Schisandrae Radix Codonopsis 
五味子 ^ 
Radix Ginseng Rubra Radix Salviae Miltiorrhizae 
紅參 ^ 
Radix Angelicae Sinensis Rhizoma Polygonati Odorati 
當歸 ^ 
Table 1. Ten TCMs commonly used for treating heart diseases 
After first screening of the mitogenic effect of the commonest four TCMs in our 
target list, two of them namely Radix Astragali (黃民）and Radix Ophiopogonis (麥 
冬)were found to have mitogenic effect on neonatal primary day 1 SD rat 
cardiomyocytes for more than 30 % (Fig.l). However, Radix Aconiti Lateralis 
Preparata ( 制附子 ) d i d n ' t show any significant mitogenic effect on rat 
cardiomyocytes while Cortex Periplocae (香力口皮）might even inhibit the growth of 
cardiomyocytes. As a result, the mitogenic effect of both Radix Astragali and Radix 
Ophiopogonis on both neonatal primary day 1 and day 7 SD rat cardiomyocytes as 
10 
Introduction 
well as H9C2 cardiac cell line would be further studied first. 
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Fig.l. The ^H-thymidine incorporation of day 1 primary rat cardiomyocytes after 
treating with different TCMs for 3 days was compared with its own control, in which 
PBS was added instead of TCMs. Data are mean 土 SEM (n=3). * P< 0.01. 
1.5.1 Radix Astragali 
According to the rule of Chinese pharmacopeia. Radix Astragali were served as 
drugs, which have been prescribed for centuries for general debility, chronic illness, 
and to increase the overall vitality of the system. Currently, much of the 
pharmacological research is focused on its immune stimulating polysaccharides and 
other active ingredients from the plant, which are useful in treating immune 
deficiency conditions. Although Radix Astragali，which is also named as Huang Qi 
(HQ) has demonstrated a wide range of immunopotentiating effects (Chu, et al., 
1994; Yoshida, et al,, 1997) and has proven efficacious as an adjunct cancer therapy 
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(Cha et al., 1994; Lau et al, 1994), astragalus saponins were found to exert a 
positive effect on the function of the heart through the inhibition of the formation of 
lipid peroxides in the myocardium as well as by decreasing blood coagulation and 
blood pressure. Notwithstanding many clinical studies on the treatment of ischemic 
heart disease (Li et al., 1995), myocardial infarction (Chen et al, 1995) as well as 
heart failure (Luo et al., 1995) with HQ farther supported its cardioprotective effects, 
its mechanism involved is still uncertain and the molecular role playing in the cardiac 
growth and development is still unknown. 
1.5.2 Radix Ophiopogonis 
Radix Ophiopogonis with a common name of Mai Dong (MD) is one of the 
major components in the Sheng-Mi-San (SMS) traditional Chinese formulation used 
for coronary artery disease for centuries. In general, MD was prescribed in 
combination with other Chinese medicinal herbs like Radix Ginseng and Fructus 
Schisandrae and it was found to be effective in protecting the heart against 
myocardial infarction (Dong and Chen, 1983), isoproterenol-induced myocardial 
injury and ischemia-reperfusion injury in isolated rat heart (Li et al., 1996b). 
Furthermore, myocardial infarct size was found to be reduced through the activation 
of protein kinase C and opening of mitochondrial KATP channel (Wang et al” 2001; 
Wang et al., 2002). Besides improving the cardiac hemodynamics after myocardial 
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infarction, and arrhythmia (Shu, 1984)，a low dosage of ophiopogonsides and 
ophiopogon total amino-acids could increase the cardiac output by increasing the 
contractility of cardiomyocytes (Mo et al., 1991). Although recent studies showed 
that MD was one of the potential TCM for treating heart diseases, its effect together 
with its molecular role playing in heart development are still not explored. 
Given that, there were different species of Radix Ophiopogonis and Radix 
Astragali among different provinces, Radix Ophiopogonis originated from Shanxi 
(山西）and Radix Astragali originated from Zhejiang (、浙、江）were purchased from the 
Hip Hing Loong Co. Hong Kong and would be used in my study. 
13 
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Chapter 2 MATERIALS & METHODS 
2.1 Materials 
Detailed Information 
Radix Astragali Purchased from Hip Hing Loong Co. Hong Kong 
Radix Ophiopogonis Purchased from Hip Hing Loong Co. Hong Kong 
Sprague-Dawley rats Obtained from the animal house of the Chinese 
University of Hong Kong 
H9C2 cardiac cells Purchased from ATCC (Cat. No: CRL-1446), a 
subclone of the original clonal cell line derived from 
embryonic BDIX rat heart tissue by B. Kimes and B. 
Brandt and exhibits many of the properties of skeletal 
muscle. 
Dulbecco's modified Purchased from Gibco (Cat. No: 12400) and 1.5g/L 
Eagle Medium/F12 sodium bicarbonate was added before preparing the 
(DMEM/F12) DMEM/F12 culture medium, pH7. 
Dulbecco's modified Purchased from Sigma (Cat. No: D1152) and 1.5g/L 
Eagle Medium (DMEM) sodium bicarbonate was added before preparing the 
DMEM culture medium, pH7. 
Selective medium . DMEM/F12 with 0.1% insulin-transferrin-selenium-G 
supplement (ITSG, Gibco), 5% horse serum (HS), 
0.75% penicillin-streptomycin (PS, Invitrogen), 
0.1 mM ascorbic acid and 0.1 mM 5-bromo-2'-deoxy-
uridine (BrdU, Sigma) 
Plating medium Selective medium with 5% fetal bovine serum (FBS, 
Invitrogen) and 1% PS 
Low serum medium Contained DMEM and M199 in 4:1 ratio with 0.5% 
HS, 0.1% ITSG and 0.25% PS 
Differentiation medium DMEM with 3% HS and 0.3% PS 
Culture medium DMED with 5% FBS and 0.5% PS 
Complete medium DMEM with 10% FBS and 1% PS 
Mayer's hemalum Purchased from Sigma (Cat. No: MHS-16) 
solution 
Eosin Y solution Purchased from Sigma (Cat. No: HT110-2-16) 
Trypan blue stain (0.4%) Purchased from Invitrogen (Cat. No: 15250-061) 
[methyl-^H] thymidine Purchased from Amersham (Cat. No: TRK637-lmCi) 
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Hi Safe 2 Liquid Purchased from Perkinelmer Life Sciences (Cat. No: 
Scintillation Cocktail 1200-436) 
5-Bromo-2'-deoxy-uridine Purchased from Roche (Cat. No: 1444611) 
Labeling and Detection 
Kit III 
Cyanine 3-dCTP NEL576 Purchased from PerkinElmer (Cat No: NEL576) 
Cyanine 5-dCTP NEL577 Purchased from PerkinElmer (Cat No: NEL577) 
GFX-96 PGR Purification Purchased form Amersham (Cat. No: 25-6902-02) 
Kit 
Microarray Purchased from Amersham ( Cat. No: RPK0325) 
Hybridization Buffer 
Version 2 
3 -actin PGR primers Purchased from Invitrogen 
DDAH PCR primers Purchased from Invitrogen 
HO-3 primers Purchased from Invitrogen 
Cyclin B PCR primers Purchased from Invitrogen 
Table 2. List of materials used 
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2.2 Cell Culture 
2.2.1 Primary neonatal rat cardiomyocytes cell culture 
Heart ventricles from 1-day-old or 7-day-old Sprague-Dawley rats were 
dissected and washed in 15 ml ice-cold Hepes-BS with 40U/ml heparin (Sigma). 
After that, the heart ventricles were washed 3 times with 15 ml ice-cold Hepes-BS 
and then minced with scissors in 1 ml of Hepes-BS in a glass universial. The minced 
heart tissues were washed with 15 ml ice-cold Hepes-BS to remove blood cells and 
trypsinized at 4°C for 20 hr. After static incubation, the trypsin solution was removed 
and the tissues were transferred to a 50 ml round-bottom centrifuge tube with 15 ml 
Hepes-BS. After centrifugation at 200xg for 3 min at 20°C, the tissues were 
transferred to 10 ml pre-warmed digestion solution in a 25 ml Erlenmeyer flask and 
incubated at 37°C for 15 min with occasional stirring. Then, the tissues were 
dispersed 10 times by pipetting up and down with a 10 ml pipette. The cell 
suspension was transferred to a 50 ml round-bottom centrifuge tube and centrifuged. 
The pellet was resuspended and washed with 20 ml Hepes-BS with CaCh and MgCh. 
After centrifugation at 200xg for 5 min at 20�C，the supernatant was removed and 
the pellet was resuspended in 20 ml plating medium. For selective enrichment of 
cardiomyocytes, cell suspension was poured through a sieve (Sigma) into the 140mm 
culture dishes and was then preplated at 37°C in a humidified incubator with 5% CO2 
16 
Materials & Methods 
for 1 hr. After that, the resultant cell suspension was plated in either 24-well culture 
plates (2.6 x 10^ cells/well) or 6-well culture plates (1.2 x 10^ cells/well) with 
Dulbecco's modified Eagle Medium/F 12 (DMED/F-12, Gibco) containing 0.1% 
insulin-transferrin-selenium-G supplement (ITSG, Gibco), 5% horse serum (HS), 
0.75% penicillin-streptomycin (PS, Invitrogen), 0.1 mM ascorbic acid and O.lmM 
bromodeoxyuridine (BrdU, Sigma) in order to prevent the proliferation of 
nonmyocytes. After 48-hr culturing at 37°C in a humidified incubator with 5% CO2， 
the selective medium was replaced with low serum medium and was further cultured 
for 4 days during which pre-warmed low serum medium was refreshed at alternative 
day. 
2.2.1.1 Mayer's hemalum-eosin staining 
After discarding the low serum medium of the primary neonatal rat 
cardiomyocytes prepared in 2.2.1, 0.5 ml Mayer's hemalum staining reagent was 
added and incubated for 3 min. Then washing step was carried out by adding 1 ml 
water and was incubated for 5 min. After that, 0.5 ml acidified eosin Y solution was 
added to further stain the cells for 3 min. It was followed by washing the cells with 1 
ml water for 3 min and dehydrating the cells by stepwise addition of 70%, 96% and 
100% ethanol solution for 3 min each time. 
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2.2.2 Primary rat fibroblasts cell culture 
Similar as the preparation of primary neonatal rat cardiomyocytes, primary rat 
fibroblasts were prepared by centrifuging the supernatant remained in the prepared 
rat heart cells after centrifugation at 200xg for 5 min at 20°C before the pre-plating 
steps that was mentioned in 2.2.1. After centrifuging the mentioned remaining 
supernatant at l,000xg for 10 min at 20°C, the pellet was resuspended in 20 ml 
DMEM medium with 10% FBS and 1%PS. Then the resultant cell suspension was 
plated in 24-well culture plates with 1 x 10^  cells / well and was cultured at 37°C in a 
humidified incubator with 5% CO2. 
2.2.3 H9C2 cardiac cell culture 
H9C2 cardiac cells, purchased from American Type Culture Collection (ATCC, 
Cat. No: CRL-1446), are muscle cell line derived from embryonic rat heart tissue. 
Normally, H9C2 cardiac cells were cultured in flask with DMEM supplemented with 
10% FBS and 1% PS (complete medium) in order to maintain the cells at 
undifferentiated stage. Meanwhile, confluent H9C2 cardiac cells were induced to 
differentiate by culturing in differentiation medium, in which DMEM containing 5% 
HS and 0.5% PS for 8 days. Finally, both undifferentiated and differentiated H9C2 
cardiac cells were maintained at humidified incubator at 37°C with 5% CO2. 
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2.3 TCMs Preparation and Treatment 
2.3.1 Preparation of TCMs powder from aqueous extracts 
200g of dried herb was washed thoroughly with distilled water and cut into 
small pieces before they were soaked in 600ml distilled water overnight. Then they 
were boiled at 100°C for 3 hr under reflux. After centrifuging the hot-water extracted 
herb solution at 8,000 rpm for 10 min to remove insoluble ingredients, the 
supernatant was frozen at -70 °C for about 2 weeks followed by lyophilization, using 
the lyophilizer Savant ModulyoD (ThermoSavant, Holbrook, NY). After that, TCM 
powder from the herb aqueous extract was obtained and was stored in an air-tight box at 
-20 °C. By repeating the above steps, the powder form of ten different TCMs (listed in 
Table 1) were prepared. 
2.3.2 Preparation of culture medium with TCMs powder 
The lyophilized TCM powder was re-dissolved in 10ml phosphate-buffered 
saline (PBS) before filter-sterilization by using a 0.22 \xm filter. After that, the TCM 
stock solution was then further diluted in different final concentrations with either 
complete medium or culture medium for treating H9C2 cardiac cells or neonatal 
primary rat cardiomyocytes respectively. 
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2.3.3 Pre-treatment of undifferentiated and differentiated H9C2 
cardiac cells with TCMs 
The undifferentiated H9C2 cells, seeded either in 24-well plates with 1.5 x 10^  
cells per well or in 6-well plates with 3 x 10^  cells per well, were treated with 
different concentrations of TCMs for different time points whereas those treated with 
complete medium containing the same concentration of PBS instead of TCMs were 
used as control. After that, the H9C2 cardiac cells were either induced to differentiate 
with differentiation medium or remained undifferentiated in complete medium before 
performing tritiated thymidine or 5-Bromo-2‘-deoxy-uridine (BrdU) assays. 
2.3.4 Post-treatment of differentiated H9C2 cardiac cells with 
TCMs 
H9C2 cardiac cells were seeded in 24-well plates with 1.5 x 10^ cells per well or 
in 6-well plates with 3 xlO^ cells per well. Then, they were induced to differentiate 
by culturing in differentiation medium for 8 days. After that, the differentiated H9C2 
cardiac cells were treated with different concentrations of TCMs in complete 
medium for different time points while those treated with PBS instead were 
considered as control. 
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2.4 Assessment of DNA Synthesis and Proliferation 
Given that reentry into S-phase is the crucial step for the induction of 
regenerative growth, direct assessment of DNA synthesis by quantitating tritiated 
thymidine or BrdU incorporation into the newly synthesized DNA of replicating cells 
can be used as the early marker for proliferation. However, in order to further prove 
that the increase in DNA synthesis was really accompanied with cell division, the 
number of viable cells was counted. This was done by permeability assay, in which 
the damaged leaky cells were stained blue while the viable cells remained unstained 
with trypan blue stain. 
2.4.1 Tritiated thymidine incorporation assay 
Briefly, final concentration of 1 |iCi/ml of [methyl-^H] thymidine (Amersham) 
was added to the treated and untreated cells in 24-well plates with 0.5 ml complete 
medium and were further incubated at 37°C with 5% CO2 for 8-12 hr. Then, the cells 
in each well were washed with 0.7 ml PBS twice and were fixed by adding 0.3 ml 
ice-cold 70% ethanol at 4°C for 30 min. After that, the cells were washed with 0.7 ml 
PBS twice again and were then lysed with 0.5 ml 1% sodium dodecyl sulphate (SDS) 
solution. 0.4 ml sample, taken from each well, was then added to a scintillation vial 
containing 4 ml Hi Safe 2 Liquid Scintillation Cocktail fluid (PerkinElmer Life 
Sciences) and its radioactivity was determined by a liquid scintillation counter. 
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2.4.2 5-Broino-2'-deoxy-uridine (BrdU) assay 
BrdU assay is a safer assessment for DNA synthesis by making use of 
non-radioactive isotopes. Actually, it is almost as sensitive as tritiated thymidine 
assay. According to the BrdU Labeling and Detection Kit III (Roche), the treated and 
untreated cells, seeded in 24-well plates, were first labeled with 10 }aM BrdU 
labeling solution in 0.5 ml complete medium and were incubated at 37°C with 5% 
CO2 for 8 hr. Then, the labeling solution was removed and the cells were washed 
with 0.7 ml PBS containing 10% FBS for 3 times. After that, 0.5 ml pre-cooled 70% 
ethanol in 0.5M HCl was added and the cells were incubated at -20°C for 30 min in 
order to fix the cells. Then, the cells were washed with 0.7 ml PBS containing 10% 
FBS for 3 times before adding 0.3 ml nuclease working solution and incubated at 
37°C for 30 min. After washing with 0.7 ml PBS containing 10% FBS for 3 times, 
the cells were incubated with 0.3 ml anti-BrdU-peroxidase (anti-BrdU-POD) solution 
at 37°C for 30 min. Then, the cells were washed with 0.7 ml PBS for 3 times before 
adding 0.4 ml peroxidase substrate. After that, the cells were incubated at room 
temperature under dark condition until green color products were formed and the 
absorbance reading of the samples was then measured by a microtiter plate reader at 
405nm with a reference wavelength at 490nm. 
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2.4.3 Cell counting 
H9C2 cells were first seeded with 3 x 10^  cells per well in 6-well plates. After 
treating with different concentrations of TCMs for different time points, 200 |il of 
trypsin was added into each well to detach the cells. Then, 300 complete medium 
was added to inactivate the trypsin. After mixing well, 100 |li1 cell suspension was 
then transferred into an eppendorf and mixed with 100 |al trypan blue stain (Gibco)， 
in which 30 of the sample solution was loaded into the chambers of 
hemocytometer. Under light microscope, the viable unstained cells can be 
distinguished and counted according to the formula mentioned below. 
C = N X 104 X dilution factor 
where C = cells per milliliter 
N = average of cells counted 
1 o4 = volume conversion factor for 1 m m � 
2.4.4 Statistical analysis 
All data obtained from tritiated thymidine incorporation assay, BrdU assay and 
cell counting were presented as % control, in which the tritiated thymidine uptake, 
BrdU uptake and the viable cell number after TCM treatment were compared with 
that of the untreated cells according to the following formula. 
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data of TCM-treated cells — data of untreated cells 
o/o control = X 100% 
data of untreated cells 
Statistical significance was determined by One-way ANOVA: Multiple comparisons 
(Post Hoc tests) and would be presented as P value. In fact, data with P value less 
than 0.05 were considered to be statistically significant. 
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2.5 Screening of Differentially Expressed Genes in H9C2 
Cells after TCM Treatment by cDNA Microarray 
2.5.1 Total RNA extraction 
TCM-treated and untreated cells, seeded in 100 mm dishes, were first washed 
with diethyl pyrocarbonate (DEPC)-treated PBS for twice before being lysed with 3 
ml TRIzol® Reagent (Invitrogen, Life Technologies) at room temperature for 5 min. 
Then, the Trizol mixture were transferred to 1.5 ml tubes and centrifuged at 
12,000xg for 10 min at 4°C. After centrifugation, the supernatant was transferred 
into a new tube with 0.3 ml chloroform. The tube was then shaken vigorously for 15 
sec and was incubated at room temperature for 2 min. After that, the 
Trizol/chloroform mixture was centrifliged at ll,400xg for 15 min at 4°C and the 
upper aqueous layer was then transferred into a new tube with 0.75 ml isopropyl 
alcohol. After mixing well by inversion, the mixture was incubated at room 
temperature for 10 min and was centrifuged at ll,400xg for 10 min at 4°C. 
Following centrifugation, the supernatant was discarded and the pellet was washed 
with 1 ml 70% pre-cooled ethanoL After centrifugation at 12,000xg for 10 min at 
4°C, the supernatant was discarded and the pellet was dried in an oven at 70°C until 
it became semi-transparent. Then, the RNA pellet was eluted in 25 [i\ DEPC-treated 
sterile distilled water, from which 2 |il RNA sample was mixed with 2 [L\ 1 xRNA 
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loading dye (60% formamide, 7% formaldehyde, 1.25xMOPS, 12.5 mM EDTA, 
0.03% bromophenol blue, 0.03% xylene cyanol FF，150 iig ethidium bromide). The 
sample was denatured at 65°C for 5 min and then chilled on ice for 2 min 
immediately before loading into a 1% TAE agarose gel. RNA sample showing sharp 
28S and 18S rRNA bands at an approximate intensity ratio of 1.5:1 to 2:1 under UV 
visualization was considered to be intact and was stored at -70°C. Besides, quantity 
and quality of each RNA sample were determined spectrophotometrically by A260 
and A260 /A280 ratio respectively, in which pure RNA was obtained if A260 /A28O ratio 
was around or lager than 2. 
2.5.2 RNA labeling 
Intact total RNA sample with high purity prepared in 2.5.1 was used to 
synthesize fluorescent cDNA probe using direct labeling method described below. 
2.5.2.1 Synthesis of fluorescence labeled probe 
For primer annealing, 100 \xg total RNA from TCM-treated H9C2 cells or 
untreated H9C2 cells prepared in 2.5.1 together with either 3 spike Cy3 RNA 
(Amersham) or 3 [i\ spike Cy5 RNA (Amersham) was mixed with 600 pmol of 
anchored oligo-dT primer and DEPC-treated water to a final volume of 30 ^il. Then, 
the sample was incubated at 65°C for 10 min and chilled on ice immediately before 
adding 30 fal of reaction mixture including 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 
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10 mM DTT, 2.5 mM MgCb, 200 }iM of unlabelled dNTP, 100 |LIM of either 
Cyanine 3-dCTP NEL 567 or Cyanine 5-dCTP NEL 577 (PerkinElmer) and 800 units 
of superscript II MMLV reverse-transcriptase. After that, all samples were incubated 
at 42°C for 1 hr and a booster with additional 200 units of SuperScript II MMLV 
reverse-transcriptase was further added to each sample before incubating for an 
additional 45 min. In order to stop the reaction and to degrade the remaining RNA， 
20 III of O.IN NaOH and 2 mM EDTA was added to each reaction sample and was 
incubated at 65°C for 30 min before adding 20 \i\ of O.IN HCl for neutralization. 
2.5.2.2 Purification of fluorescence labeled probe 
The fluorescent labeled probes were purified by GFX-96™ PGR Purification 
Kit (Amersham). This was done by loading the fluorescence labeled probe to the 
binding plate with 300 |LI1 of capture buffer in each well. After mixing with pipette 
and centrifuging at l,800xg for 2 min, the unincorporated nucleotides and short 
oligomers collected in the wash plate were discarded. Then, 400 i^l of wash buffer 
was added to each well and the plate was spanned at l，800xg for 5 min. After 
removing the collected liquid waste and centrifuging the plate for an additional 30 
sec, the wash plate was discarded and replaced by the collection plate. To elute out 
the incorporated fluorescence labeled nucleotides, 50 of elution buffer was added 
to each well and was incubated at room temperature for 1 min. After that, the plate 
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was centrifuged at l,800xg for 2 min and the purified fluorescence labeled probe was 
obtained in the collection plate. 
2.5.3 Microarray hybridization 
2.5.3.1 Concentration of fluorescence labeled probe 
Given that a probe with high concentration can give a better and higher signal, 
the collected purified fluorescence labeled probe was further concentrated by heating 
at 95°C for 20 min in the PGR machine until around 10-20 of the final volume 
was obtained. 
2.5.3.2 Hybridization 
The concentrated Cy3 and Cy5 fluorescence labeled probes were mixed together 
before adding with 20 |il Microarray Hybridization Buffer Version 2 (Amersham) 
and 2.8 of poly-dA (Sigma). Then, the mixed probe was denatured at 95°C for 2 
min and 40 |il of formamide (Sigma F9037) was added afterwards. Before adding the 
denatured fluorescence labeled probe onto our own subtracted cDNA microarray 
slides from the subtraction library clones between day 1 and day 7 SD rat ventricular 
myocardium, all particulates were removed by dusting the slide surface and the 
LifterSlip丁M Cover Glass (Erie Scientific Company) with compressed air. The 
fluorescence labeled probe was allowed to spread evenly under the cover slip via the 
capillary action with the aid of forceps and care was taken in order to avoid any air 
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bubbles trapped inside. Then, the slide was placed inside a hybridization chamber, 
which was covered by an aluminium foil to avoid photo-bleaching of the 
fluorescence labeled probe. After that, the hybridization chamber was placed inside 
an air-bath incubator and was hybridized at 42°C for 18 hr. 
2.5.3.3 Post-hybridization treatment 
After removing the slide from the hybridization chamber, it was washed by 
2xSSC wash 1 solution with 0.03% SDS in a falcon. The cover slide was then 
removed carefully by using forceps. After that, the falcon was agitated gently at room 
temperature for 2 min and the slide was removed and transferred to the IxSSC wash 
2 solution with the aid of forceps. Again, the falcon was agitated gently at room 
temperature for another 2 min. The above washing procedure was repeated but using 
different washing solution in the sequence of 0.2xSSC and then O.lxSSC washing 
solution. Lastly, the slide was spun dry by centrifugation in MSB Mistral 2000 at 
IjOOOxg for 10 min before scanning. 
2.5.4 Data collection 
2.5.4.1 Scanning of slide 
For array scanning, ScanArray® 4000 Microarray Analysis System (Packard 
Bioscience, BioChip Technologies) was used, by which the slide was scanned at 
532nm and 635nm for detecting Cy3 and Cy5 fluorescence respectively. In fact, the 
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power of each laser (Cy3 or Cy5) and the PTM gain, which controlled the 
fluorescence signal balancing and the greatest dynamic range respectively were 
adjusted carefully until the optimum parameter for the images scan was obtained. 
2.5.4.2 Image processing: spots finding and quantification 
After scanning, the raw Cy3 and Cy5 images were processed using Dapple 
software (http://www.cs.washington.edu/homes/jbuhler/dapple), which is a tool for 
microarray segmentation, spot-finding and quantification. Then, a 16-bit, grayscale 
TIFF image of both Cy3 and Cy 5 channels of the array slide was loaded and the 
array geometry was set to perform mostly-automated grid placement. For our slides, 
the grids were set as 12 rows times 2 columns for arrays and 12 rows times 32 
columns for spots. After the grids were adjusted to the most satisfactory place 
manually, the spots were found and circled by the program automatically. The spots 
were then inspected and marked as either "accept" or "reject" by clicking over the 
spot. Once the spots were insj^ected and edited, they were quantified by the program 
and the data were exported by choosing output as text files. 
2.5.5 Data normalization and analysis 
After quantifying the spots, the exported data were normalized and analyzed by 
Lucidea™ Microarray ScoreCard software (Amersham) and spike RNA, in which 
Cy3 fluorescence signal was normalized with respect to Cy5 fluorescence signal and 
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those spots under detection limit (3 S.D. less than 48 spots of negative control) were 
excluded in all experiments. In order to get a compatible output file to the input file 
for the ScoreCard, the format of the output file from the Dapple was first converted 
into a list that contained information of the element (clone position), DxA (density x 
area, sum of all pixels in spot) and sDxA ( background subtracted intensity). After 
that, the converted file was input to the Lucidea Microarray ScoreCard. The control 
plate position (recommended as the first plate), sample-channel assignment and 
colour coded method were set for analysis. After data processing, a quality report and 
normalized data file with associated clone information were produced and these 
tab-delimited text files were viewed by the Excel program for clarity. 
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2.6 Confirmation of Differentially Expressed Genes in 
H9C2 Cells after TCM Treatment by RT-PCR 
Besides synthesizing fluorescent cDNA labeled probe, intact total RNA sample 
with high purity prepared in 2.5.1 was used as a template for total cDNA synthesis 
and performing reverse transcription-polymerase chain reaction (RT-PCR). 
2.6.1 DNase I digestion of total RNA sample 
Intact total RNA sample was subjected to 2 units DNase I，Amp Grade 
(Invitrogen, Life Technologies) with 1 xDNase I reaction buffer (20 mM Tris-HCl, 2 
mM MgC12, 50 mM KCl) arid DEPC-treated water in a final volume of 50 |il. The 
reaction mixture was then incubated at room temperature for 15 min and 5 |xl of 25 
mM EDTA was added. After that, the reaction mixture was heated at 6 5 � C for 10 min 
to inactivate the DNase I digestion following by putting the sample on ice for 2 min 
immediately. Then, 2 |il DNase I digested RNA sample was mixed with 2 |il IxRNA 
loading dye before loading into a 1% TAE agarose gel. The integrity of RNA was 
checked by the sharp 28S and 18S rRNA bands at an approximate intensity ratio of 
1.5:1 to 2:1 under UV visualization before being stored at -70°C. 
2.6.2 First-strand cDNA synthesis 
DNase I digested total RNA was first mixed with 2.5 i^l of 100 i^M oligo-dT 
primer and DEPC-treated water to a final volume of 50 [il The mixture was 
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incubated at 65°C for 5 min and chilled on ice immediately. After that, 50 |j,l master 
mix with final concentration of 1 xcDNA synthesis buffer (25 mM Tris acetate, 37.5 
mM potassium acetate, 4 mM magnesium acetate, stabilizer), 0.0IM DTT，2 mM 
dNTP, 4 units RNase OUT, 15 units ThermoScript Reverse Transcriptase (Invitrogen, 
Life Technologies) was added to each RNA-primer sample and was then incubated at 
55°C for 1 hr in a PCR machine. The annealing process was terminated by heating at 
85°C for 10 min and the sample was chilled on ice immediately. Then, 2 units RNase 
H was added to each sample and was incubated at 37°C for 20 min to remove any 
un-transcribed RNA remained. Finally the first-strand cDNA synthesized was stored 
at -20°C. 
2.6.3 RT-PCR of the candidate genes 
Total RNA extracted from cells after different days of TCM treatment using 
TRIzol® Reagent was subjected to DNase I digestion before using as a template for 
cDNA synthesis. For the normalization of cDNA template of all samples, PCR was 
performed using 5 units Taq DNA Polymerase (Amersham Biosciences) with rat 
cytoplasmic ^ -actin house keeping gene forward primer (5'AGGCATCGCTGACA 
GGATGCAGAA3，) and reverse primer (5'GCGCAAGTTAGGTTTTGTCAAAG 
A3，）in the presence of 200 |iM dNTP mix, IxPCR buffer (10 mM Tris-Cl, 1.5 mM 
MgCb, 50 mM KCl, 0.1% Triton X-100) and sterile distilled water in a final volume 
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of 25 III. PGR reaction was subjected to denaturation at 94°C for Imin, followed by 
different cycles of amplification at 94�C for 36 sec, 58°C for 36sec，72°C for 1 min 
30 sec using PTC-100 Programmable Thermal Controller (MJ Research). The PGR 
product was aliquoted at different reaction cycles and analyzed in 1% TAE agarose 
gel with ethidium bromide, by which the band intensity of /3 -actin gene with 
molecular size of 388 b.p. can be quantified by a densitometer. 
After normalizing the amount of sample cDNA added for the template to give 
the same amount of ^ -actin PGR product for all samples, primers for the candidate 
genes, N-G, N-G-dimethylarginine dimethylaminohydrolase (DDAH), heme 
oxygenase-3 (HO-3) and cyclin B were designed. For amplifying N-G, 
N-G-dimethylarginine dimethylaminohydrolase gene and cyclin B gene, forward 
primer (5，GGCCGTGGTGTGCGAGGAGAC 3') with reverse primer (5， 
TGGGGTTCGGTGCAGCAAGAC 3') and forward primer (5，CTGGATGTG 
CACCTGCCGAAGAA 3') with reverse primer (5' GCCCCAGCTGCAA 
TTTGAGAAGG 3，) were used respectively in the PGR reaction with the same PGR 
reaction profile for 冷-actin gene. However, forward primer (5' GGAAGCAGAT 
GACCGGGCAGAA 3，）and reverse primer (5' CCGGCTGGGTCTCCTTCTTCA 3，） 
were employed to amplify heme oxygenase-3 gene with the same PGR profile except 
the annealing temperature was changed to 53°C for 36 sec. After PGR reaction was 
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completed, the PGR product was aliquoted at different reaction cycles and analyzed 
in 1% TAE agarose gel with ethidium bromide. The band intensity of the target gene 
with its own particular amplified molecular size, was then quantified by a 
densitometer. In fact, the molecular size of the amplified PGR products of N-G, 
N-G-dimethylarginine dimethylaminohydrolase, heme oxygenase-3 and cyclin B 




Chapter 3 RESULTS 
3.1 Neonatal Primary Rat Cardiomyocytes 
3.1.1 Preparation of high-purity neonatal primary rat 
cardiomyocytes 
Currently the use of cultured cardiac cells is taking an increasing relevance due 
to the versatility, economy and convenience of the methodology as compared to 
whole animal experiments. Although neonatal primary rat cardiomyocytes are 
well-established for pharmacological, physiological and biochemical studies, cells 
isolated from rat hearts still contain a large proportion of mesenchymal cells (mainly 
fibroblasts). Therefore, elimination of non-muscle mesenchymal cells based on the 
different characteristics between muscle and non-muscle cells such as speed of 
attachment to the plate surface, cell density and proliferation rate were employed. In 
our experiment, the proportion of cardiomyocytes were greatly increased by 
pre-plating the isolated cells in culture dishes for 1 hr since mesenchymal cells have 
a faster rate of attachment to the plate surface than cardiomyocytes do (Blondel et al., 
1971). Also, O.lmM BrdU, acted as a proliferation inhibitor for the growth of 
non-muscle cells, was added in selective medium and the selected cells were further 
cultured in low-serum medium in order to eliminate the mesenchymal cells. As 
evaluated by the Mayer's hemalum-eosin staining method shown in Fig. 2, over 90% 
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of cardiomyocytes were obtained, in which the cytoplasm of myocytes stained as red 
color while the mesenchymal cells (fibroblasts) stained as pale blue color (Simpson 
et al., 1982; Xu et al., 1999). 
Fig. 2. By the Mayer's hemalum-eosin staining method, the cytoplasm of the 
myocytes were stained red while the mesenchymal cells (fibroblasts) were stained 
pale blue and over 90% yield of purified cardiomyocytes were obtained. 
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3.1.2 Neonatal primary rat cardiomyocytes ceased to undergo DNA 
replication after 6-day in vitro culturing 
Provided that ^H-thymidine incorporation in both day 1 and day 7 SD primary 
rat cardiomyocytes decreased dramatically and remained steadily low after in vitro 
culturing for 6 days (Fig. 3), we could assume that there was limited significant 
proliferative growth of the cardiomyocytes after 6-day in vitro culturing. 
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Fig. 3. Both day 1 and day 7 primary rat cardiomyocytes after culturing in low serum 
medium for 4，6 and 8 days were pulse labeled with 1 |LiCi/ml of ^H-thymidine for 8 




Thus, the neonatal primary rat cardiomyocytes prepared in 2.2.1 would be 
cultured for 6 days in vitro before treating with different TCMs so as to make sure 




3.1.3 Both MD and HQ promoted the growth of day 1 primary rat 
cardiomyocytes in dose- and time-dependent manners 
^H-thymidine incorporation assay was done on the day 1 primary rat 
cardiomyocytes after treating with different concentration of TCMs for 2 or 3 days. 
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Fig. 4. The ^H-thymidine incorporation of day 1 primary rat cardiomyocytes after 
treating with different concentration of MD for 2 or 3 days was compared with its 
own control, in which PBS was added instead of MD. Data are mean 土 SEM (n=3). 
* P< 0.05 and ** P< 0.005. 
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Fig. 5. The ^H-thymidine incorporation of day 1 primary rat cardiomyocytes after 
treating with different concentration of HQ for 2 or 3 days was compared with its 
own control, in which PBS was added instead of HQ. Data are mean 土 SEM (n=3). 
* P< 0.05. 
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Both Fig. 4 and Fig. 5 showed that after treating the day 1 primary rat 
cardiomyocytes with different concentration of either MD or HQ, the ^H-thymidine 
uptake increased in dose- and time-dependent manners at the lower concentration 
range (i.e. below 1 mg/ml). It was also found that 1 mg/ml of MD, by which 41% 
and 44% increases of ^H-thymidine uptake were recorded after treating the 
cardiomyocytes for 2 and 3 days respectively, was the most effective dosage in 
promoting the DNA synthesis in the day 1 primary rat cardiomyocytes while 3-day 
treatment of 1 mg/ml HQ could even promote the DNA synthesis of day 1 primary 
rat cardiomyocytes by 89%. 
However, the promotion of DNA synthesis decreased when the concentration of 
MD and HQ increased to 2 mg/ml or above. Although both MD and HQ were found 
to have mitogenic effect on day 1 primary rat cardiomyocytes, the mitogenic effect 
on day 7 primary rat cardiomyocytes would be studied in order to have a better 
understanding on the growth of cardiomyocytes. Since rat cardiomyocytes switch 
from hyperplastic to hypertrophic growth between day 3 and day 4 postnatal (Clubb 
and Bishop, 1984; Li et al., 1996a), TCM which can promote both day 1 and day 7 




3.1.4 HQ is more potent than MD in promoting the growth of day 7 
primary rat cardiomyocytes 
Again, ^H-thymidine incorporation assay was done on the day 7 primary rat 
cardiomyocytes after treating with 0.5，1 and 2 mg/ml MD or HQ for 2 days. 
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Fig. 6. The ^H-thymidine incorporation of day 7 primary rat cardiomyocytes after 
treating with different concentration of MD or HQ for 2 days was compared with its 




Although both MD and HQ do have mitogenic effect on day 7 primary rat 
cardiomyocytes as the ^H-thymidine uptake was increased after 2-day treatment of 
MD or HQ (Fig. 6)，HQ seemed to be more potent than MD in promoting the DNA 
synthesis in day 7 primary rat cardiomyocytes. With reference to Fig. 6，there was 
around 1.8 fold of increase in ^H-thymidine uptake after treating the cardiomyocytes 




3.2 H9C2 Cardiac cells 
Apart from neonatal primary rat cardiomyocytes, H9C2 cardiac cells were used 
as another cell model to further confirm the proliferative effect of MD and HQ on 
cardiomyocytes during cardiac development. In order to investigate whether the 
mitogenic effect of MD and HQ is possibly due to the induction of intracellular 
signal molecules, which may further mediate the differential gene expression that 
regulate the cell cycle or proliferation during differentiation process, pre-treatment 
on the H9C2 cardiac cells before inducing differentiation was also performed. 
3.2.1 Proliferative effect of MD and HQ on undifferentiated H9C2 
cardiac cells 
Provided that MD and HQ do exert a mitogenic effect on day 1 and day 7 
neonatal primary rat cardiomyocytes, the proliferative effect of MD and HQ on 
undifferentiated H9C2 cardiac cells was first studied in order to find the effective 
dosage and time point before performing pre-treatment study. 
Based on previous screening results on neonatal primary rat cardiomyocytes, 
different concentration of MD and HQ was further narrowed down and added to 
undifferentiated H9C2 cardiac cells respectively for different time period before 
^H-thymidine incorporation assay or BrdU assay was performed. 
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Fig. 7. The BrdU incorporation of the undifferentiated H9C2 cardiac cells after 
treating with different concentration of MD for 1 or 3 days was compared with its 
own control, in which PBS was added instead of MD. Data are mean 土 SEM (n=3). 
* P< 0.05 and **P< 0.005. 
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Fig. 8. The ^H-thymidine incorporation of undifferentiated H9C2 cardiac cells after 
treating with different concentration of HQ for 12，24 and 36 hr was compared with 
its own control, in which PBS was added instead of HQ. Data are mean 士 SEM (n=3). 
* P< 0.05. 
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As similar result as those obtained on the neonatal primary rat cardiomyocytes, 
both MD and HQ promoted DNA synthesis in undifferentiated H9C2 cardiac ells in 
dose- and time- dependent manners, in which about 25 to 42% increase of 
proliferation index was obtained after treating the H9C2 cardiac cells with 0.5 and 
1 mg/ml of MD respectively (Fig. 7) while HQ, which is more potent than MD, 
exerted the similar proliferative effect (about 40% increase) on H9C2 cardiac cells as 
that MD did at a lower dosage (around 0.2mg/ml) in a shorter time period (about 24 
hr) (Fig. 8). And this increase of proliferation index was further supported by the 
increase of cell number using trypan blue exclusion test, in which a 25% increase of 
cell number was obtained when the cells were treated with 0.5mg/ml of MD for 3 
days (Table 3) and 20% to 25% increase of cell number were obtained after treating 
the cells with 0.2 mg/ml HQ for 24 to 36 hr respectively (Table 4). 
Days of Treatment 0.1 mg/ml MD 0.5 mg/ml MD 
1 个 6 士 9 o/o 5 ± 9 o/o 
2 个 13.8 ±6 o/o 个 11±8o/o 
3 个 1 0 . 5 土 5 o/o 个 25.7 士 4 o/o 
Table 3. The increase of viable cell number of undifferentiated H9C2 cardiac cells 
after treating with different concentration of MD for 1, 2 and 3 days was compared 




Hours of Treatment 0.1 mg/ml HQ 0.2 mg/ml HQ 
12 ^^  0.2 ±13 o/o 个 7.9 ±5 o/o 
24 个 6.1 ± 8 o/o 个 20.8 ±50/0 
36 个 6.5 ± 5 0/0 个 2 4 . 8 土 2 % 
Table 4. The increase of viable cell number of undifferentiated H9C2 cardiac cells 
after treating with different concentration of HQ for 12，24 and 36 hr was compared 




3.2.2 Pre-treatment of HQ on H9C2 cardiac cells during 
differentiation 
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Fig. 9. (A) The BrdU incorporation profile of the control H9C2 cardiac cells during 
differentiation. (B) The BrdU incorporation of H9C2 cardiac cells, which were 
pre-treated with 0.1 or 0.2 mg/ml HQ for 24 hr before inducing differentiation for 
different days was compared with its own control, in which PBS was added instead 
of HQ. Data are mean 士 SEM (n=6). * P< 0.01. 
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According to Fig. 9 (A), the BrdU incorporation of H9C2 cardiac cells 
decreased dramatically after 3 days of differentiation induction and it remained low 
after 5 days of induction. This indicated that DNA synthesis of H9C2 cardiac cells 
remained low and nearly terminated after 5-day differentiation induction and 
therefore H9C2 cardiac cells were believed to be fully differentiated after 5-day 
differentiation induction. Besides, Fig. 9 (B) showed that pre-treatment of H9C2 
cardiac cells with HQ generally gave a higher proliferative index than the control in 
dose- and time-dependent manners during differentiation and 0.2mg/ml HQ, which 
was the optimal concentration found from the undifferentiated H9C2 cardiac cell 
study, exerted the greatest ability to increase the DNA synthesis of H9C2 cardiac 
cells during differentiation. 
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3.2.3 Pre-treatment of MD and HQ on differentiated H9C2 cardiac 
cells 
H9C2 cardiac cells were pre-treated with different concentration of either MD 
for 3 days or HQ for 12，24 and 36 hr before inducing differentiation for 8 days. 
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Fig. 10. The BrdU incorporation of H9C2 cardiac cells, which were pre-treated with 
0.1，0.5 or 1 mg/ml MD for 3 days before inducing differentiation for 8 days was 
compared with its own control, in which PBS was added instead of MD. Data are 
mean 士 SEM (n=6). * P< 0.01. 
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Fig. 11. The ^H-thymidine incorporation of H9C2 cardiac cells, which were 
pre-treated with 0.05, 0.1 or 0.2 mg/ml HQ for 12，24 and 36 hr before inducing 
differentiation for 8 days was compared with its own control, in which PBS was 
added instead of HQ. Data are mean 士 SEM (n=6). * P< 0.01. 
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In Fig. 10, the proliferation index (i.e. the percentage of BrdU incorporation of 
the sample over the control) had increased 7.4% and 21.5% in H9C2 cardiac cells 
pre-treated with 0.1 and 0.5 mg/ml MD respectively after inducing differentiation. 
However, the proliferation index decreased with higher MD concentration. 
Meanwhile, the ^H-thymidine incorporation of differentiated H9C2 cardiac cells was 
increased by pre-treating the cells with HQ (Fig. 11). It was also found that about 
45% and 69% increase of DNA synthesis was resulted if the H9C2 cardiac cells were 
pre-treated with 0.2 mg/ml HQ for 24 and 36 hr respectively. 
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3.2.4 Post-treatment of MD on differentiated H9C2 cardiac cells 
H9C2 cardiac cells were seeded in 24-well plates with 1.5 x 10^ cells per well. 
Before being induced to differentiate by culturing in differentiation medium for 8 
days, some of the cells were pre-treated with 0.1，0.5 and 1 mg/ml MD for 3 days 
while the others remained untreated. Then, the differentiated H9C2 cardiac cells 
were post-treated with different concentration of MD for 3 days and BrdU assay was 
done. 
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Fig. 12. The BrdU incorporation of pre-treated H9C2 cardiac cells and the 
pre-treated + post-treated H9C2 cardiac cells with different concentrations of MD 
was compared with its own control, in which PBS was added instead of MD. Data 
are mean 土 SEM (n=3). * P< 0.05 and ** P< 0.001. 
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Fig. 12 showed that DNA synthesis of differentiated H9C2 cardiac cells was 
increased after MD post-treatment. However, when compared with the MD 
post-treated H9C2 cardiac cells, in which only about 25 % increase of proliferation 
index was obtained after post-treating the cells with 0.5 mg/ml MD for 3 days, the 
increase of DNA synthesis was much greater in H9C2 cardiac cells with both MD 
pre-treatment and post-treatment. And, Fig. 12 indicated that nearly 60% increase of 
proliferation index could be reached by both pre-treating and post-treating the cells 
with 0.5 mg/ml MD for 3 days. 
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3.3 Primary Rat Fibroblasts 
Mesenchymal cells, mainly fibroblasts, are one of the main cell types in our 
heart. Actually, they are not involved in the contractility of the heart and unlike 
cardiomyocytes, they usually respond to growth factor by hyperplastic growth. 
However, cardiac fibroblast hyperplasia is a common feature of pathological cardiac 
remodeling, which leads to increased extracellular matrix deposition and cardiac 
fibrosis (Brilla et al.’ 1996; Weber, 2000). Therefore，TCM which can particularly 
promote cardiomyocytes growth but not the other cell types, especially the 
fibroblasts, is of great potential in treating heart diseases based on the regeneration of 
adult myocardium. 
In the following experiment, the mitogenic effect of both MD and HQ on 
primary rat fibroblasts was studied. Primary rat fibroblasts, seeded in 1 x 10^ cells per 
well of a 24-well plate, were treated with 0.5，1 or 2 mg/ml MD or HQ for 2 days 
respectively. Then, ^H-thymidine incorporation assay was done. 
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3.3.1 Proliferative effect of MD and HQ on primary rat fibroblasts 
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Fig. 13. The ^H-thymidine incorporation of primary rat fibroblasts after treating with 
different concentration of MD or HQ for 2 days was compared with its own control, 
in which PBS was added instead of TCM. Data are mean 士 SEM (n=3). * P< 0.05 
and ** P< 0.005. 
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According to Fig. 13, DNA synthesis in primary rat fibroblasts was increased 
significantly after MD treatment, in which 2.7-fold of increase was obtained after 
treating with 0.5 mg/ml MD, while HQ didn't exert any or much proliferative effect 
on primary rat fibroblasts with the effective dosage (i.e. < 1 mg/ml) used for primary 
rat cardiomyocytes. In fact, the DNA synthesis in primary rat fibroblasts was 
increased greatly only if the cells were treated with high concentration of HQ where 
2 mg/ml HQ caused nearly 2.5-fold increase of thymidine incorporation comparing 
to the control. 
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3.4 Screening of Differentially Expressed Genes in H9C2 
Cells after HQ Treatment by cDNA Microarray 
Provided that HQ could promote cardiomyocytes growth without affecting other 
cell types in the heart at the dosage below 1 mg/ml, 0.2mg/ml HQ, which was the 
optimal concentration found from the previous studies, was used to treat both 
undifferentiated and differentiated H9C2 cardiac cells. Then, the genes that were 
found to be differentially expressed after HQ treatment by using cDNA microarray 
technique and our own subtracted cDNA microarray slides from the subtraction 
library clones between day 1 and day 7 SD rat ventricular myocardium were 
analyzed by Lucidea™ Microarray ScoreCard software (Amersham) and the data 
were plotted.. 
3.4.1 Differentially expressed genes in undifferentiated H9C2 
cardiac cells after HQ treatment 
Cy and 
Cy 5 labeled cDNA, which was with ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
mg/ml HQ for hr before were 
on our own cDNA 
microarray chip. Provided that after scanning, 
Cy 3 was as green and Cy 5 
Fig. 14. The hybridized cDNA 
60 microarray chip after scanning 
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was visualized as red color, those genes that were equally expressed in HQ-treated 
and control undifferentiated H9C2 cardiac cells would be visualized as yellow spots 
while down-regulated genes were shown as green spots and up-regulated genes were 
indicated as red spots by HQ treatment. So，a particular gene was said to be 
up-regulated only if a negative log (Cy3/Cy5) reading of that gene was obtained 
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Fig. 15. The unnormalized log (Cy3/Cy5) ratio in undifferentiated H9C2 cardiac 
cells after treating with 0.2 mg/ml HQ for 24 hr, which was labeled with Cy 5 
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Fig. 16. The normalized log (Cy3/Cy5) ratio in undifferentiated H9C2 cardiac cells 
after treating with 0.2 mg/ml HQ for 24 hr, which was labeled with Cy 5 fluorescent 
dye, was compared with its Cy 3 labeled own control using PBS instead. 
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With reference to the normalized log (Cy3/Cy5) ratio obtained in Fig. 16，those 
genes that were differentially regulated by HQ treatment by at least 3-fold would be 
further studied. Therefore, some known genes with log (norm Cy3/Cy5) ratio value 
of greater than 0.5 or lesser than -0.5 were listed in Table 5. 
Category Fold of change Genes description 
Rattus norvegicus Drosophila polarity 
4 . 8 个 
gene (frizzled) homologue mRNA 
Rattus norvegicus mRNA for protein 
4.2 ‘ kinase (MUK) 
4.1 t Rat mRNA for beta-globin 
Rattus norvegicus heme oxygenase-3 
3 . 6 个 
Signal Transduction/ (HO-3) mRNA 
Rattus norvegicus mRNA for Mss4 
Cell Regulation/ 5.6 t protein 
Development Rattus norvegicus mRNA for N-G, 
3.3 t N-G-dimethylarginine 
dimethylaminohydrolase 
Rattus norvegicus mRNA for hereditary 
• haemochromatosis-like protein 
Rattus norvegicus PP-1 alpha mRNA for 
9.3 i catalytic subunit of protein phosphatase 
type 1 alpha 
5.6 个 Rat cardiac troponin T mRNA 
Rattus norvegicus cis-Golgi p28 (p28) 
Contractile Elements/ 3.8 f 
mRNA 
Cytoskeketon Related 5 j Rat gene encoding skeletal muscle actin 
3.9 i Rat mRNA encoding alpha-tubulin 
Rattus norvegicus ribosomal protein 




“ Rat mRNA for MRC OX-45 surface 
Membrane Associated 3.3 \ . 
antigen 
Table 5. Differentially expressed genes in undifferentiated H9C2 cardiac cells by at 
least 3-fold after treating with 0.2 mg/ml HQ for 24 hr 
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3.4.2 Differentially expressed genes in differentiated H9C2 cardiac 
cells after HQ treatment 
Besides investigating the differentially expressed genes in undifferentiated 
H9C2 cardiac cells, those genes that were differentially regulated by the 
post-treatment of 0.2 mg/ml HQ for 24 hr on differentiated H9C2 cardiac cells would 
also be studied so as to have a better insight in the genes that regulate the switch 
from hyperplastic to hypertrophic growth by comparing and correlating these two 
pools of differentially expressed genes. 
Therefore, H9C2 cardiac cells were induced to differentiate in differentiation 
medium for 8 days before treating either with PBS as control or 0.2 mg/ml HQ for 24 
hr. However, the control cDNA was labeled with Cy 5 fluorescent dye and the HQ 
treated cDNA was labeled with Cy 3 fluorescent dye, which was different from the 
previous experiment. In fact, reverse labeling was done in order to eliminate the bias 
in any experimental steps such as the differences in labeling efficiency of the 
fluorescent dye and the sensitivity of the scanner for different fluorescent dye. In this 
experiment, the up-regulated genes would be visualized as green and gave a positive 
log (Cy3/Cy5) reading while down-regulated ones would be shown as red spots with 
a negative log (Cy3/Cy5) reading as shown in the scatter-plot graphs (Fig. 17，Fig. 
18). Also, some known genes with log (norm Cy3/Cy5) ratio value of greater than 
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0.5 or lesser than -0.3 were listed in Table 6. 
2 _ ： 
• • • 
• 一 • • \ . -r • 
. • - • • : ' • • log (unnormCy3/Cy5) 
- - • ••• • • : • I J •i C _ — •• - — -- — 
1 5 i v -::-- • • • • • - - � 
、'X •• • - • • • • 
» -U _ "S -• • • . • • ... -
1 一 ^ — — - - - — — — — I . J-.^- • • 
L O - ••、•• 一.•• • • … 
t � • • • •"•. _ •• • y ；•. .; • ' - . 
各 0.5 f ••: • 、 
I � i 5 2 5 




1 _ _ _ . _ _ . _ i ‘ - - . - -- — — — — — — — — 
-1.5 
log (Cy5) 
Fig. 17. The unnormalized log (Cy3/Cy5) ratio in differentiated H9C2 cardiac cells 
after treating with 0.2 mg/ml HQ for 24 hr, which was labeled with Cy 3 fluorescent 
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Fig. 18. The normalized log (Cy3/Cy5) ratio in differentiated H9C2 cardiac cells 
after treating with 0.2 mg/ml HQ for 24 hr, which was labeled with Cy 3 fluorescent 
dye, was compared with its Cy 5 labeled own control using PBS instead. 
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Category Fold of change Genes description 
Q 个 Rattus norvegicus pregnane X receptor 
‘ mRNA 
18 Q 个 Rattus norvegicus development-related 
protein mRNA 
7 2 t Rattus norvegicus PKCd gene encoding 
protein kinase C delta 
G 2 t Rattus norvegicus mRNA for hereditary 
haemochromatosis-like protein 
5.8 个 R. norvegicus mRNA for Mss4 protein 
Rattus norvegicus ryanodine receptor type 
Signal Transduction/ 个 II (RATRYR2) mRNA 
Cell Regulation / 5 q 个 Aspergillus oryzae nitrogen regulatory 
‘ protein OTam gene 
Development 3 g 个 Rattus norvegicus gene for histamine 
‘ N-methyltransferase 
Homo sapiens protein kinase 
2.5 i (cAMP-dependent, catalytic) inhibitor 
gamma (PKIG) 
2 4 I Rattus norvegicus farnesoid X activated 
‘ receptor 
2 1 ^ Rattus norvegicus solute carrier family 3， 
• member 1 (Slc3al) 
2 1 j Rat sodium-hydrogen exchange 
‘ protein-isoform 4 (NHE-4) mRNA 
17.3 t Rat mitochondrial 12S and 16S rRNA 
Rattus norvegicus cytochrome c oxidase 
16.6 个 subunit I (Co I) 
Energy Metabolism f Rattus norvegicus mitochondrial genome 
mRNA for cytosolic malate 
5 8 个 
‘ dehydrogenase 
Rattus norvegicus mitochondrial 
‘ cytochrome oxidase subunits 
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I Rat mitochondrial ndl gene for NADH 
11./ I 
dehydrogenase subunit 1 
, … I Rattus norvegicus PI mRNA for ATP 
Energy Metabolism 2.2 | 
synthase subunit c 
Rat mitochondrial ATP synthase beta 
2.2 ^ 
subunit mRNA 
Rat 45 S rDNA gene transcription 
18.8 I 
initiation region 
Rat mRNA for chromosomal protein 
‘ HMG2 
Rattus norvegicus ribosomal protein L21 
11.7 t 
Replication / mRNA 
Rattus norvegicus 16S ribosomal RNA 
Transcription / 9.9 个 
gene 
Translation Translation elongation factor 1 alpha 1 
• (EEFlAl) 
Rattus norvegicus gene for 
3.4 个 hepatocarcinogenesis-related transcription 
factor (HTF) 
Mus musculus Balb/c zinc finger protein 
2.3 PZF (Pzf) mRNA 
Rattus norvegicus voltage-dependent 
49-0 t anion channel 2 (VDAC2) mRNA 
Rattus norvegicus degenerin channel 
t MDEG mRNA 
3.5 t Rattus norvegicus mRNA for Tim 17 
Membrane Associated Mus musculus transmembrane 9 
3 2 个 
• superfamily member 2 (Tm9sf2) 
, Rattus norvegicus voltage-dependent 
2 4 1 
‘ anion channel 1 (Vdacl) 
Rat mRNA for MHC class II antigen 
• RTl.B-1 beta-chain 
Rattus norvegicus mRNA for collagen 
Extracellular Matrix / 7.8 t alpha 2 type V 




5 Rattus norvegicus mRNA for proteasomal 
• ATPase (MSSl) 
7.0 t Rattus norvegicus CDK109 mRNA 
Others 
3.8 i Mus musculus chromosome 1 
Drosophila melanogaster X BAG 
‘ RP98-6J12 
Table 6. Differentially expressed genes in differentiated H9C2 cardiac cells by at 
least 2-fold after treating with 0.2 mg/ml HQ for 24 hr 
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3.4.3 Comparison of differentially expressed genes in both 
undifferentiated and differentiated H9C2 cardiac cells after 
HQ treatment 
Referring to those genes listed in Table 5 and Table 6，ribosomal proteins, 
hereditary haemochromatosis-like protein and Mss4 protein, which is also known as 
GDP-releasing protein or guanine nucleotide releasing protein, were found to be 
up-regulated by HQ treatment in both undifferentiated and differentiated H9C2 
cardiac cells. Interestingly, they are both related in signal transduction and cell 
regulation. For example, Mss4 protein, interacting with several members of the Rab 
family, has role implicated in Ca^^-dependent exocytosis of neurotransmitters 
(Andriamampandry et al., 2002; Strick et al” 2002) and its regulation of intracellular 
transport may be of importance for the function and growth of human tumor cells 
(Muller-Pillasch et al” 1997). In addition, hereditary haemochromatosis-like protein 
was found to be involved in iron homeostasis (Parkkila et al, 1997; Salter-Cid et al., 
1999), and ribosomal proteins were found to be related to protein synthesis (Achard 
et al, 2002). Besides, it was also found that more proportions of genes participating 
in energy metabolism, cell replication, transcription and translation were found to be 
up-regulated in differentiated H9C2 cardiac cells. 
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3.5 Confirmation of Differentially Expressed Genes in 
H9C2 Cells after HQ Treatment by RT-PCR 
Based on the preliminary results of differentially expressed genes in H9C2 
cardiac cells after HQ treatment obtained from the microarray analysis, the mRNA 
expression level of N-Q N-G-dimethylarginine dimethylaminohydrolase was first 
confirmed to be up-regulated by HQ in undifferentiated H9C2 cardiac cells (Fig. 19). 
Although further experiments are needed to be performed in order to confirm the 
remaining genes that were differentially regulated by HQ, the mRNA expression 
level of cyclin B was studied in the differentiated H9C2 cardiac cells after HQ 
post-treatment (Fig. 21). As cyclin B promoted G j M transit in the cell cycle after 
forming complex together with cdc2, investigation of cyclin B gene expression in 
differentiated H9C2 cardiac cells would give us better information on whether the 
cells reenter the cell cycle and undergo mitosis after HQ post-treatment. 
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3.5.1 Preferential up-regulation of N-Q N-G-dimethylarginine 
dimethylaminohydrolase mRNA expression level in 
undifferentiated H9C2 cardiac cells after HQ treatment 
Lane: 1 2 3 4 5 6 7 
388 b.p. - -
Fig. 19. RT-PCR analysis of N-G, N-G-dimethylarginine dimethylaminohydrolase 
gene expression level in HQ-treated (Lanes 5 & 7 for 33 & 37 cycles respectively) 
and untreated (Lanes 4 & 6 for 33 & 37 cycles respectively) undifferentiated H9C2 
cardiac cells using /?-actin gene expression after 25 PGR cycles (Lanes 1 & 2 in 
untreated and HQ-treated respectively) as internal normalization where 100 b.p. 
marker was used (Lane 3). 
7 4 
Results 
3.5.2 Preferential up-regulation of heme oxygenase-3 mRNA 
expression level in undifferentiated H9C2 cardiac cells after 
HQ treatment 
Lane: 1 2 3 4 5 
I 
Fig. 20. RT-PCR analysis of heme oxygenase-3 gene expression level in HQ-treated 
(Lanes 3 & 5 for 35 & 37 cycles respectively) and untreated (Lanes 2 & 4 for 35 & 
37 cycles respectively) undifferentiated H9C2 cardiac cells using ^-actin gene 
expression after 25 PGR cycles (Lanes 1 & 2 in untreated and HQ-treated 




3.5.3 Preferential up-regulation of cyclin B mRNA expression level 
in differentiated H9C2 cardiac cells after HQ treatment 
Lane: 1 2 3 4 5 6 7 
— 646 
• 
Fig. 21. RT-PCR analysis of cyclin B mRNA expression level in HQ-treated (Lanes 3 
& 5 for 26 & 29 cycles respectively) and untreated (Lanes 2 & 4 for 26 & 29 cycles 
respectively) differentiated H9C2 cardiac cells using /3-actin gene expression after 25 
PGR cycles (Lanes 6 & 7 in untreated and HQ-treated respectively) as internal 
normalization where 100 b.p. marker was used (Lane 1). 
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Chapter 4 DISCUSSION 
Proliferation and differentiation are two different aspects of cell growth. Unlike 
many other regenerative organs like liver, adult heart was once termed as the 
"terminally differentiated organ". This is probably due to the phenomenon that 
cardiomyocytes undergo replication and proliferation during fetal and early postnatal 
life but lose their proliferative capacity and cease to undergo DNA replication soon 
after birth. Thus, subsequent growth of cardiomyocytes is solely via hypertrophy 
rather than hyperplasia. Although whether cardiomyocytes are terminally 
differentiated remains controversial despite the increasing evidence of new myocytes 
formation in the adult heart (Anversa and Kajstura, 1998)，the molecular mechanisms 
that regulate the rapid transition from hyperplasia to hypertrophy in cardiomyocytes 
remains obscure. 
On this basis, in vitro preparations of neonatal rat cardiomyocytes as well as 
H9C2 cardiac cell line were used in my study for the analysis of the molecular 
control of the cell cycle in an attempt to identify the key factors of terminal 
differentiation of cardiomyocytes. As cardiomyocytes switch from hyperplastic to 
hypertrophic growth between days 3 and 4 postnatal in rat (Clubb and Bishop, 1984; 
Li et al., 1996a), TCM which is able to induce mitogenic effect on both day 1 and 
day 7 postnatal SD rat cardiomyocytes will be a potential target for further 
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investigation on the genes expression that govern the hyperplastic to hypertrophic 
growth. And by using cDNA microarray technique and our own subtracted cDNA 
microarray slides from the subtraction library clones between day 1 and day 7 SD rat 
ventricular myocardium, we can have a better understanding of the genes expression 
and their underlying mechanisms that are modulated by those effective mitogenic 
TCMs on cardiomyocytes. 
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4.1 HQ Being a More Effective Mitogenic TCM than MD 
on Cardiomyocytes Exerted its Effect in Dose- and 
Time Dependent Manners 
In this study, both MD and HQ were found to exert mitogenic effect on neonatal 
primary day 1 and day 7 SD rat cardiomyocytes as well as H9C2 cardiac cell line. 
Given that 1 mg/ml HQ could promote DNA synthesis in both day 1 and day 7 
neonatal primary rat cardiomyocytes by 89% (Fig. 5) and 1.8 fold (Fig. 6) 
respectively whereas 1 mg/ml MD could only cause 44% and 37% increase in DNA 
synthesis of both day 1 (Fig. 4) and day 7 (Fig. 6) neonatal primary rat 
cardiomyocytes, that were treated for the same period of time accordingly, HQ was 
believed to be more potent than MD in promoting DNA synthesis in cardiomyocytes. 
Although the mitogenic effect of both MD (Fig. 4) and HQ (Fig. 5) was in dose- and 
time- dependent manners at the low concentration range, their mitogenic effect 
reached optimal at 1 mg/ml and decreased with the further increase of concentration. 
This might be probably due to the toxic effect of the TCM itself on the 
cardiomyocytes and this could also explain why a different optimal concentration of 
HQ was found to have mitogenic effect on H9C2 cardiac cells since different cell 
types or cell nature might show different sensitivity to the same TCM. 
As similar result obtained as primary rat cardiomyocytes, both MD (Fig. 7) and 
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HQ (Fig. 8) did exert mitogenic effect on undifferentiated H9C2 cardiac cells. 
However, the optimal treatment condition of HQ was 0.2 mg/ml for 24 hr, which was 
far different from those obtained in primary culture except that of MD was more or 
less the same in both primary culture and H9C2 cardiac cell culture study. 
Consistently, HQ was also found to be more potent than MD in promoting DNA 
synthesis in undifferentiated H9C2 cardiac cells as HQ could enhance the same 
proliferative effect (about 40%) as MD did (Fig. 7) at a lower dosage (around 
0.2mg/ml) in a shorter time period (about 24 hr) (Fig. 8). 
Although the increase of DNA synthesis, documented by the rise in 
^H-thymidine incorporation and BrdU incorporation, which indicated the transition 
from Gi to S phase, was recorded after treating the undifferentiated H9C2 cardiac 
cells with both MD and HQ, the concern of whether the newly synthesized DNA of 
replicating cells was really accompanied with cell division was raised. 
Provided that many species cardiomyocytes increase their DNA synthesis upon 
multinucleation without cytokinesis (Brodsky et al., 1988; Clubb and Bishop, 1984) 
or by DNA repair, only direct viable cell counting after MD and HQ treatment on 
undifferentiated H9C2 cardiac cells could confer the cells were proliferating. 
Referring to Table 3，a 25% increase of cell number was obtained when the cells 




to 25% increase of cell number were obtained after treating the cells with 0.2 mg/ml 
HQ for 24 to 36 hr respectively. As a result, both HQ and MD could enhance 
neonatal cardiomyocytes proliferation, which were consistent with the previous data 
obtained in both ^H-thymidine and BrdU incorporation assays. And this increase in 
DNA synthesis was probably coupled with cell division, but not due to the 
mutinucleation or DNA repairing processes. Also, both MD and HQ might have a 
high potential capability in promoting cardiomyocyte growth, in particular the 
regulation on the rapid hyperplasia to hypertrophy switch in myocardial development 




4.2 Mitogenic Effect of Both MD and HQ might Possibly 
Due to the Regulation of Intrinsic Factors 
Although both MD and HQ could enhance DNA synthesis and promote the 
growth in neonatal cardiomyocytes and undifferentiated H9C2 cardiac cells, little is 
known about whether their mitogenic effect is due to intrinsic or extrinsic factors. In 
an attempt to have a better insight in whether the mitogenic effect of MD and HQ 
was mediated through regulating the intrinsic factors such as genes expression rather 
than through the transient extrinsic hormonal modulation, pre-treatment of MD and 
HQ were performed. 
As pre-treatment of both MD (Fig. 10) and HQ (Fig. 11) could enhance the 
DNA synthesis of differentiated H9C2 cardiac cells, it was possible that their 
mitogenic effect on H9C2 cardiac cells might involve the regulation of intrinsic 
factors, through which might further modulate the differential gene expression that 
regulate the cell cycle or proliferation. 
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4.3 HQ Rather Than MD Showed a Higher Specificity in 
Promoting DNA Synthesis in Cardiomyocytes 
In spite of the high potential of both MD and HQ to initiate cardiac growth by 
altering the gene expression, MD was found to have great potential in reinitiating 
DNA synthesis in differentiated H9C2 cardiac cells. Since the BrdU incorporation of 
differentiated H9C2 cardiac cells after MD post-treatment was increased and 
synergistic effect was recorded by both pre-treating and post-treating the cells (Fig. 
12), MD might help the differentiated H9C2 cardiac cell to overcome the Gi block in 
the cell cycle. However, whether this mitogenic effect was specific to 
cardiomyocytes, but not other cell types was still a main problem needed to be 
tackled in order to be able to treat heart diseases based on the regeneration of adult 
myocardium. 
Although over 90% of primary rat cardiomyocytes were obtained (Fig. 2) and 
H9C2 cardiac cell, which is a cell line derived from embryonic BDIX rat heart tissue 
with skeletal properties was used in my study, there was still a certain possibility that 
some other cardiac non-muscle cells e.g. fibroblasts were present. Provided that 
cardiac fibroblast hyperplasia is a common feature of pathological cardiac 
remodeling, which leads to increased extracellular matrix deposition and cardiac 
fibrosis (Brilla et al.’ 1996; Weber, 2000), TCM which could specifically enhance the 
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growth of cardiomyocytes would be our main target to be studied. 
In this study, only MD had showed a significant mitogenic effect on primary rat 
fibroblast (Fig. 13), in which 2.7-fold of increase was obtained after treating with 0.5 
mg/ml MD. Although 1 mg/ml HQ could promote DNA synthesis on primary rat 
fibroblasts for 44% (Fig. 13)，a much greater i.e. 89% increase of DNA synthesis was 
resulted if day 1 primary rat cardiomyocytes were treated with the same 
concentration of HQ (Fig. 5). 
In addition, the turnover rate of fibroblasts was faster than cardiomyocytes; 
therefore, it was possible that HQ might have a higher specificity in promoting the 
DNA synthesis in cardiomyocytes rather than MD did. Besides, HQ could only exert 
a remarkable proliferative effect on primary rat fibroblasts at a dosage larger than 1 
mg/ml. Since the effective dosage of HQ used for promoting cardiomyocyte growth 
was within the range of 1 mg/ml, it was inferred that HQ could preferentially 
enhance the growth of cardiomyocytes during development while MD exerted its 
mitogenic effect on both fibroblasts and cardiomyocytes or mainly on fibroblasts. 
Thus, the differential gene expression of both undifferentiated and differentiated 
H9C2 cardiac cells after treating 0.2 mg/ml HQ for 24 hr would be studied so as to 
further elucidate the molecular mechanism that regulate the rapid transition from 
hyperplasia to hypertrophy in cardiomyocytes. 
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4.4 The Differentially Expressed Genes were Supported by 
The Clinical Functions of HQ 
According to the results obtained from cDNA microarray, some putative 
differentially expressed known genes were found to be related to the clinical 
functions of HQ. Surprisingly, N-G, N-G-dimethylarginine dimethylaminohydrolase 
(DDAH) and heme oxygenase-3 (HO-3) were found to be up-regulated by 3.5 fold 
and 3.6 fold after treating undifferentiated H9C2 cardiac cells with 0.2 mg/ml HQ for 
24 hr (Table 5). 
Given that enhanced expression of DDAH could increase nitric oxide synthase 
(NOS) activity via metabolizing the endogenous NOS inhibitor, asymmetric 
dimethylarginine (ADMA), endogenous nitric oxide (NO) synthesis would be 
increased (Achan et al., 2002; Ueda et al., 2003). Also, carbon monoxide (CO) 
generated in living organisms during the degradation of heme by the enzyme heme 
oxygenase, which exists in constitutive (HO-2 and HO-3) and inducible (HO-1) 
isoforms, is known to dilate blood vessels in a manner similar to nitric oxide (Chen 
et al., 2003; Ndisang et al., 2003; Rossi et al., 2003; Wang et al.，1997). In addition, 
NO and CO were recently shown to protect cardiomyocytes from 
hypoxia-reoxygenation and ischemia-reperfusion injuries (Mehta et al,, 2002; 
Vulapalli et al., 2002), which might give us some hints on the clinical 
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cardioprotective effects of HQ against hypertension (Castillo et al, 1993), ischemic 
heart disease (Li et al., 1995), myocardial infarction (Chen et al., 1995) and heart 
failure (Luo et al” 1995). 
In addition, NO was believed to play a modulatory role in myocardial 
excitation-contraction coupling (Kaye et al.’ 1996) through ryanodine receptors 
(Stoyanovsky et al.’ 1997), which was found to be up-regulated by 5 fold after 
treating HQ on differentiated H9C2 cardiac cells (Table 6) whereas the inhibition of 
sodium-hydrogen exchanger before ischemia could protect against 
ischemia-reperflision injury (Castella et al., 2003). In fact, sodium-hydrogen 
exchange protein-isoform 4 (NHE-4), which was down-regulated by 2 fold after HQ 
treatment (Table 6)，might be one of the possible modulators of the underlying 
mechanisms of HQ in treating ischemic heart disease. 
Thus, we could highly believed that the differentially expressed genes obtained 
in the undifferentiated and differentiated H9C2 cardiac cells after HQ treatment 
exhibited a high potential in modulating cardiac function, at least under 
pathophysiological conditions and during early heart development. 
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4.5 Relating the Differentially Expressed Genes with 
Cardiac Growth and Development 
In my study, 0.2 mg/ml HQ could exert its mitogenic effect on undifferentiated 
H9C2 cardiac cells, in which karyokinesis is coupled with cytokinesis since a 
significant increase in cell number was obtained. However, cell counting was not 
possible in the differentiated H9C2 cardiac cells under light microscope because the 
differentiated H9C2 cardiac cells would form a sheet of myotubules, which were 
difficult to distinguish between each cell. Thus, the gene expression of cyclin B， 
which was suggested to promote G2/M transit after forming complex with cdc2 
(Pasumarthi and Field, 2002) was studied in differentiated H9C2 cardiac cells after 
HQ post-treatment. According to RT-PCR resulted in Fig. 21, cyclin B gene 
expression was significantly up-regulated by about 2 fold after HQ post-treatment. 
This could preliminarily imply that more cells were undergoing mitosis after treating 
with 0.2 mg/ml HQ for 24 hr and this might also indicate that HQ could reinitiate 
DNA synthesis as well as cell division in differentiated H9C2 cardiac cells. But 
further confirmation by Western blot should be performed to ensure that the 
transcriptional increase of cyclin B could really lead to the biological increase of 
cyclin B activity, which in turn promotes the cell to reenter M phase in the cell cycle. 
On the other hand, by the means of RT-PCR, DDAH (Fig. 19) as well as HO-3 
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(Fig. 20) were also confirmed to be highly expressed in undifferentiated H9C2 
cardiac cells after HQ treatment. Although the heme oxygenase (HO) system has 
been strongly highlighted for its potential significance in maintaining cellular 
homeostasis in the last decade, according to recent studies, up-regulation of HO 
could not only possess anti-apoptotic properties (Ke et al, 2002; Vulapalli et al, 
2002) but also enhance proliferation (Clark et al., 1997). In fact, it was generally 
believed that carbon monoxide exposure in fetal or early neonatal life might lead to 
cardiac enlargement by causing an increased rate of hyperplasia of myocardial cells 
or continuation of hyperplasia beyond the normal period of hyperplastic growth 
(Oparil et al., 1984). 
In my study, correlation could be predicted between up-regulations of HO-3 and 
DDAH genes. As mentioned, DDAH up-regulation could possibly increase the 
endogenous NO synthesis and from current study, heme oxygenase pathway involved 
in keratinocyte proliferation, was found to be mediated by NO (Clark et al.’ 1997). 
Therefore, DDAH and HO-3 genes up-regulation might lead to a common cascade of 
intracellular signaling pathway involved in the regulation of cardiac growth and 
development during neonatal life. 
Despite the findings argued that NO exerted a general anti-proliferative effect at 
the embryonic stage by controlling the balance between cell proliferation and cell 
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differentiation (Kuzin et al.’ 1996), recent reports indicating DNA synthesis in chick 
embryo cardiomyocytes was increased via NO biosynthesis (Tantini et al., 2002). In 
fact, NOS expression, which was increased in the presence of various growth factors 
and mitogens (Gibbs, 2003) did highlight a new role for NO as a coordinator of 
proliferation. 
Interestingly, recent studies showed that protection of myocytes from 
hypoxia-reoxygenation injury by NO was mediated by the modulation of 
transforming growth factor beta-1 (TGF-/31) (Mehta et cd., 2002) and since 
Drosophila polarity gene (frizzled) homologue, which was reported to have function 
as Wnt receptors (Yang-Snyder et al., 1996), was also found to be up-regulated by 
HQ treatment on undifferentiated H9C2 cardiac cells, it was speculated that HQ 
might possibly mediate cardiac proliferation through TGF- /3 and Wnt signaling 
pathways. However, further experiments should be done in order to confirm it. 
Actually, Wnt signaling pathway, which often interacts with TGF- /5 pathway, 
has been implicated in embryological events and tumorigenesis since last decades 
(Klinedinst et al, 2003; Marvin et al., 2001; Rhee et al., 2002). Although up till now 
little is known about its regulatory mechanism due to the difficulties in Wnt receptor 
identification, a recent study documented that blockage of Wnt signaling could 
inhibit proliferation and induced apoptosis (Rhee et al., 2002). 
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Apart from Wnt and TGF- 3 signaling pathway were suspected to be involved 
in the mitogenic effect of HQ on undifferentiated H9C2 cardiac cells, 
down-regulation of catalytic subunit of protein phosphatase type 1 alpha ( P P l - a ) 
resulted from HQ treatment might facilitate the entry of S-phase in H9C2 cardiac 
cells because protein phosphatase 1 (PPl) could dephosphorylase pRb, and inhibition 
of PPl could maintain the Rb in the phosphorylated form, which could facilitate the 
transcription of S-phase genes (Nelson et al, 1997). Thus, we could inferred that HQ 
promoted the proliferative growth in neonatal undifferentiated H9C2 cardiac cells via 
triggering a complex of signaling cascades e.g. Wnt and TGF- signaling pathways, 
which in turn regulated the transcription of genes that mediate cell cycle entry or 
development. 
For the differentiated H9C2 cardiac cells, nearly different genes were found to 
be differentially modulated by HQ post-treatment despite those were mentioned in 
3.4.3. Referring to Table 6，genes that were involved in energy metabolism like 
mitochondrial cytochrome oxidase, cytochrome c oxidase, proteasomal ATPase as 
well as malate dehydrogenase and genes that were involved in protein synthesis such 
as different ribosomal proteins were accounted for the majority of up-regulation 
genes upon HQ treatment. Provided that overall increase in metabolic capacity and 
protein synthesis are prerequisite for growth and development (Achard et al.’ 2002; 
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Ji et al., 1991; Marin-Garcia et al., 1994)，HQ might possibly exerted its mitogenic 
effect on differentiated H9C2 cardiac cells via modulation of a serious of metabolic 
genes and genes that regulated protein synthesis. Also, with the up-regulation of 
transcription related genes e.g. transcription initiation region gene and elongation 
factor alpha 1 gene shown in Table 6, HQ seemed to be able to promote cardiac 
growth and development through mediating the transcription levels of target genes. 
But, whether the mitogenic effect of HQ on differentiated H9C2 cardiac cells 
resulted in either hyperplastic or hypertrophic growth or both still needed to be 
further confirmed by in vivo study. 
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4.6 The Hypothetic Mechanisms of Action that HQ 
Exerted on Cardiac Growth and Development 
To summarize, HQ might exert its proliferative effect on undifferentiated H9C2 
cardiac cells through endogenous NO/CO regulation, which might be possibly 
mediated by a complex of signaling cascades like Wnt and TGF- /9 signaling 
pathways. However, for differentiated H9C2 cardiac cells, HQ might exert its 
mitogenic effect by triggering both hypertrophic and hyperplastic growth. Since 
myocyte proliferation has been demonstrated in hypertrophic senescent heart and 
hyperplasia of myocytes might contribute to ventricular remodeling in cardiac failure 
(Olivetti et al.’ 1994: Quaini et al, 1994), hyperplasia induced by HQ in 
differentiated H9C2 cardiac cells might possibly coincide with hypertrophic growth. 
Although whether the hyperplastic growth was triggered by hypertrophic growth or 
vice versa was still remained uncertain, HQ might have a high potential in restoring 
or enhancing the proliferative reserve in cardiomyocytes during development through 
different mechanisms on different developmental stages of cardiomyocytes. And this 
is consistent with our real situation, in which myocytes were found to undergo 
continuous turnover with a subpopulation of myocytes underwent DNA synthesis 
and mitosis, another subpopulation underwent hypertrophy, and yet another group 
experienced apoptosis and necrosis (Anversa et al., 1986; Anversa et al., 1991; 
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Anversa and Olivetti, 2002). 
Also, as different groups of genes were found to be regulated by the HQ 
treatment in this study, it was likely that the mitogenic effect of HQ on 
undifferentiated and differentiated H9C2 cardiac cells was mediated via different 
intracellular signaling cascade pathways that further modulated the downstream gene 
expression controlling growth and development. 
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4.7 Future Prospect 
Although DDAH and HO-3 genes were confirmed to be up-regulated by 
RT-PCR, Western blot should be done in order to make sure that the transcriptional 
level changes of the genes were functionally effective in translation level. Also, the 
remaining differentially expressed genes would be further confirmed by RT-PCR and 
Western blot. 
4.7.1 In vivo study of HQ on the proliferation of rat cardiomyocytes 
from neonatal to postnatal development 
Although in vitro study of neonatal cardiomyocytes showed that HQ did exert 
a relatively more specific mitogenic effect than MD did, whether HQ could enhance 
the proliferation capacity of cardiomyocytes or altering the switch from hyperplastic 
to hypertrophic growth in rat during development was still largely unknown. To 
answer this question, different concentrations of HQ crude extract would be fed to 
day 1，day 7 and adult SD rats for 3 days, 7 days and 14 days before injected 
intraperitoneally (i.p.) with BrdU (50mg/kg). The HQ-treated and untreated rats 
would be decapitated 1 hr after BrdU injection and hearts would be removed rapidly 
before fixing in formalin and embedded in paraffin. Then, the histologic sections 
prepared would be stained with propidium iodide, BrdU antibody as well as 
a -sarcomeric actin antibody. Given that a -sarcomeric actin antibody is specific for 
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I bands of cardiac and skeletal muscle cells and does not reach with other isoforms 
(Skalli et al., 1988)，mitosis in myocytes could be identified and visualized by 
confocal microscopy, in which fluorescent secondary antibodies with different color 
were assigned to BrdU antibody and a -sarcomeric actin antibody. As a result, a 
better insight of the in vivo mitogenic effect of HQ during rat heart development 
could be obtained and similarly the differentially expressed genes between the 
treated and untreated rats could provide us more invaluable information on targeting 




4.7.2 The study of transgenic mice carrying the target gene regulated 
by HQ on cardiac growth and development 
In an attempt to have a functional study of the target gene that regulated cardiac 
growth and development, transgenic mice model carrying the target gene regulated 
by HQ would be established. Actually, the target gene would be cloned and the 
cardiac-restricted transgene fragments would then be microinjected into fertilized 
eggs of mice. The manipulated embryos would be transferred into the oviducts of 
pseudopregnant female mice and the offsprings were identified by PGR and Southern 
blot analysis. After analyzing the transgene expression with RT-PCR and Western 
blot, transgenic founder mice would be used to establish transgenic mouse lineages. 
As a result, not only the in vivo physiological consequences of the target gene 
overexpression could be studied but also the regenerative capacity of transgenic mice 
cardiomyocytes after myocardial infarction could be elucidated. Hopefully, in the 
foreseeable future, HQ could provide the stepping stones for the design of novel 
therapy for cardiovascular diseases based on the regeneration of myocardium and 
could restore the proper cardiac function of the heart upon injury. 
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4.7.3 The determination of active component of HQ on cardiac 
growth and development 
Although the preparation process of herbal extract was standardized, the herb 
itself may vary in their component. Therefore, in order to minimize the batch to batch 
variation of the herbal extract, besides using HPLC profiling, active component 
determination can also be performed. Since the pure compound can be synthesized or 
supplied by companies, the accuracy of drug testing can be increased. 
Although which component in HQ accounting for the mitogenic effect on 
cardiomyocytes was still uncertain, it was generally believed that astragalus saponins 
were the main component exerting effect on cardiovascular system. In fact, 
astragalus saponins owned about ten components and the majorities were 
astragaloside IV (XGA), which constituted about 0.086% to 2.4% of total astragalus 
saponins (Li and Zhang, 1998; Yao et al., 2000). According to a recent study, 
astragalosides IV could improve the cardiac function in ischemic rats in vivo (Li and 
Cao, 2002). Although the mechanism of XGA underlying the improvement of cardiac 
function was unclear, it could provide us some hints that XGA might be one of the 
active components accounting for the mitogenic effect of HQ on cardiomyocytes. 
97 I 
Discussion 
广 1 _ / 
7 M {仆OH 0 
歸 . 
on 
Fig. 22. Chemical structure of 
astragalosides IV (XGA), which was 
widely studied as the active 




Achan V，Iran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. All-trans-Retinoic 
acid increases nitric oxide synthesis by endothelial cells: a role for the induction 
of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764-769. 
Achard P, Job D, Mache R. A nuclear transcription factor related to plastid ribosome 
biogenesis is synthesised early during germination and priming. FEES Lett 2002; 
518:48-52. 
Andriamampandry C, Muller C，Schmidt-Mutter C, Gobaille S, Spedding M, Aimis 
D，Maitre M. Mss4 gene is up-regulated in rat brain after chronic treatment with 
antidepressant and down-regulated when rats are anhedonic. Mol Pharmacol 
2002; 62:1332-1338. 
Anversa P, Fitzpatrick D, Argani S, Capasso JM. Myocyte mitotic division in the 
aging mammalian rat heart. Cir Res 1991; 69: 1159-1164. 
Anversa P, Hiler B, Ricci R, Guideri G, Olivetti G. Myocyte cell loss and myocytes 
hypertrophy in the aging rat heart. J Am Coll Cardiol 1986; 8: 1441-1448. 
Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the 
adult mammalian heart. Circ Res 1998; 83: 1-14. 
Anversa P, Kajstura J, Nadal-Ginard B, Leri A. Primitive cells and tissue 
regeneration. Circ Res 2003; 92: 579-582. 
Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodeling. Nature 
2002;415:240-243. 
Anversa P, Olivetti G. Cellular basis of physiological and pathological myocardial 
growth. In: Page E，Fozzard H, Solaro RJ，eds. Handbook of Physiology. The 




Asakura A, Komaki M, Rudnicki M. Muscle satellite cells are multipotential stem 
cells that exhibit myogenic, osteogenic, and adipogenic differentiation. 
Differentiation 2001; 68: 245-253. 
Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R，Nadal-Ginard B, 
Silvestri F, Leri A, Beltrami CA, Anversa P. Evidence that human cardiac 
myocytes divide after myocardial infarction. N Engl J Med 2001; 344: 
1750-1757. 
Blondel B, Roijem I，Cheneval JP. Heart cells in culture: a simple method for 
increasing the proportion of myoblasts. Experientia 1971; 27: 356-358. 
Brilla CG, Murphy RL, Smits JF，Struijker Boudier HA, Tan LB. The concept of 
cardioreparation: Part 1. Pathophysiology of remodelling. J Cardiovasc Risk 
1996;3:281-285. 
Brodsky VY, Carlson BM, Arefyeva AM, Vasilieva lA. Polyploidization of 
transplated cardiac myocytes. Cell Differ Dev 1988; 25: 177-183. 
Capasso JM, Bruno S，Cheng W, Li P, Rodgers R, Darzynkiewicz Z, Anversa P. 
Ventricular loading is coupled with DNA synthesis in adult cardiac myocytes 
after acute and chronic myocardial infarction in rats. Circ Res 1992; 71: 
1379-1389. 
Castella M, Buckberg GD, Tan Z. Blood cardioplegic protection in profoundly 
damaged hearts: role of Na+-H+ exchange inhibition during pretreatment or 
during controlled reperfusion supplementation. Ann Thorac Surg 2003; 75: 
1238-1245. 
Castillo C, Valencia I，Reyes G，Hong E. An analysis of the antihypertensive 
properties of 3-nitroproprionic acid, a compound from plants in the genus 
Astragalus. Archivos del Instituto de Cardiologia de Mexico 1993; 1:11-16. 
Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with 
1 0 0 
References 
chemo-radio-immunotherapy and traditional Chinese medicine. Chung Hua Nei 
Ko Tsa Chih 1994: 33:46-466. 
Chen LX, Liao JZ, Guo WQ. Effects of Astragalus membranaceou on left ventricular 
function and oxygen free radical in acute myocardial infarction patients and 
mechanism of its cardiotonic action. Zhongguo ZhongXi Yi Jie He Za Zhi 1995; 
15: 141-143. 
Chen YH, Yet SF, Perrella MA. Role of heme oxygenase-1 in the regulation of blood 
pressure and cardiac function. Exp Biol Med (Maywood) 2003; 228: 447-453. 
Chien KR. Stress pathways and heart failure. Cell 1999; 98: 555-558. 
Chim SS, Cheung SS, Tsui SK. Differential gene expression of rat neonatal heart 
analyzed by suppression subtractive hybridization and expressed sequence tag 
sequencing. J a / / Biochem 2000a; 80: 24-36. 
Chim SS, Fung K, Waye MM, Lee C, Tsui SK. Expression of replication factor C 
40-kDa subunit is down-regulated during neonatal development in rat 
ventricular myocardium. J Cell Biochem 2000b; 78: 33-40. 
Chu DT，Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in 
cancer and AIDS patients induced by F3-a fractionated extract of Astragalus 
membranaceous. Chung Hua Chung Liu Tsa Chih 1994; 16:167-171. 
Clark JE, Green CJ, Motterlini R. Involvement of the heme oxygenase-carbon 
monoxide pathway in keratinocyte proliferation. Biochem Biophys Res 
Commun 1997; 241:215-220. 
Claycomb WC, Lanson NA Jr. Proto-oncogene expression in proliferating and 
differentiating cardiac and skeletal muscle. Biochem J1987; 247: 701-706. 
Clubb FJ Jr and Bishop SP. Formation of binucleated myocardial cells in the neonatal 
rat. An index for growth hypertrophy. Lab Invest 1984; 50: 571-577. 




Zhongguo ZhongXi YiJie He Za Zhi 1983; 3: 52-55. 
Engel FB, Hauck L, Cardoso MC, Leonhardt H, Dietz R, von Harsdorf R. A 
mammalian myocardial cell-free system to study cell cycle reentry in 
terminally differentiated cardiomyocytes. Circ Res 1999; 85: 294-301. 
Engelmann GL and Gerrity RG. Biochemical characterization of neonatal 
cardiomyocyte development in normotensive and hypertensive rats. J Mol Cell 
Cardiol 1 9 8 8 ; 2 0 : 1 6 9 - 1 7 7 . 
Flink IL, Oana S, Maitra N, Bahl JJ, Morkin E. Changes in E2F complexes 
containing retinoblastoma protein family members and increased 
cyclin-dependent kinase inhibitor activities during terminal differentiation of 
cardiomyocytes. J Mol Cell Cardiol 1998; 30: 563-578. 
Gibbs S. Regulation of neuronal proliferation and differentiation by nitric oxide. Mol 
Neurobiol 2003; 27: 107-120. 
Glaser R, Lu MM, Narula N, Epstein JA. Smooth musclecells, but not myocytes, of 
host origin in transplanted human hearts. Circulation 2002; 106: 17-19. 
Gruver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental 
overexpression of calmodulin induces proliferative and hypertrophic growth of 
cardiomyocytes in transgenic mice. Endocrinology 1993; 133: 376-388. 
2+ 
Guo Q, Peng TQ, Yang YZ. Effect of Astragalus membranaceus on Ca influx and 
coxsackie virus B3 RNA replication in cultured neonatal rat heart cells. 
Zhongguo ZhongXi YiJie He Za Zhi 1995; 8: 483-485 
Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. 
Cell 1994; 79: 573-582. 
Ji LL，Dillon D，Wu E. Myocardial aging: antioxidant enzyme systems and related 
biochemical properties. Am J Physiol 1991; 261(2 Pt 2): R386-392. 
Kang MJ, Kim JS, Chae SW, Koh KN, Koh GY. Cyclins and cyclin dependent 
102 
References 
kinases during cardiac development. Mol Cells 1997; 7:360-366. 
Kaye MD, Wiviott SD, Balligand J-L, Simmons WW, Smith TW, Kelly RA. 
Frequency-dependent activation of a constitutive nitric oxide synthase and 
regulation of contractile function in adult rat ventricular myocytes. Circ Res 
1996; 78:217-224. 
Ke B, Buelow R, Shen XD, Melinek J, Amersi F, Gao F, Ritter T, Volk HD, Busuttil 
RW, Kupiec-Weglinski JW. Heme oxygenase 1 gene transfer prevents 
CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via 
carbon monoxide signaling pathway. Hum Gene Ther 2002; 13: 1189-1199. 
Klinedinst SL, Bodmer R. Gata factor Pannier is required to establish competence for 
heart progenitor formation. Development 2003; 130: 3027-3038. 
Kuzin B, Roberts I, Peunova N, Enikolopov G. Nitric oxide regulates cell 
proliferation during Drosophila development. Cell 1996; 87: 639-649. 
Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth 
of murine renal cell carcinoma. Cancer Biother 1994; 9: 153-161. 
Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biol 1995; 7: 773-780. 
Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from 
hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 
1996a; 28: 1737-1746. 
Li LL, Zhang SL. Quantitative determination of cycloastragenoside and astragaloside 
IV in Radix Astragali. ChinJModAppl Pharm 1998; 15: 13-15. 
Li PC, Poon KT, Ko KM. Schisandra chinensis-dependent myocardial protective 
action of sheng-mai-san in rats. Am J Chin Med 1996b; 24: 255-262. 
Li SQ, Yuan RX, Gao H. Clinical observation on the treatment of ischemic heart 
disease with Astragalus membranaceous. Zhongguo Zhong Xi Yi Jie He Za Zhi 
1995; 15:77-80. 
1 0 3 
References 
Li ZP, Cao Q. Effects of astragaloside IV on myocardial calcium transport and 
cardiac function in ischemic rats. Acta Pharmacol Sin 2002; 23: 898-904. 
Luo HM, Dai RH, Li Y. Nuclear cardiology study on effective ingredients of 
Astragalus memhranaceou in treating heart failure. Zhongguo Zhong Xi Yi Jie 
He Za Zhi 1995; 15:707-709. 
Marin-Garcia J, Ananthakrishnan R, Agrawal N，Goldenthal MJ. Mitochondrial gene 
expression during bovine cardiac growth and development. J Mol Cell Cardiol 
1994; 26: 1029-1036. 
Marvin MJ, Di Rocco G, Gardiner A, Bush SM, Lassar AB. Inhibition of Wnt 
activity induces heart formation from posterior mesoderm. Genes Dev 2001; 15: 
316-327. 
McGill CJ and Brooks G. Cell cycle control mechanisms and their role in cardiac 
growth. Cardiovasc Res 1995; 30: 557-569. 
Mehta JL, Chen HJ, Li DY. Protection of myocytes from hypoxia-reoxygenation 
injury by nitric oxide is mediated by modulation of transforming growth 
factor-beta 1. Circulation 2002; 105: 2206-2211. 
Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K， 
Vilquin JT, Marolleau JP. Myoblast transplantation for heart failure. Lancet 
2001;357:279-280. 
Mo ZJ，Jiang GC, Ran L，Huang K, Yang ZW，Xiao R，Xiao ZY. Pharmacological 
studies on the active constituents of Ophiopogon japonicus. HuaXi YaoXue Za 
Z/7/1991;6: 13-15. 
Morgan DO. Principles ofCDK regulation. Nature 1995; 374:131-134. 
Muller-Pillasch F, Zimmerhackl F, Lacher U, Schultz N, Hameister H, Varga G, 
Friess H, Buchler M, Adler G, Gress TM. Cloning of novel transcripts of the 
human guanine-nucleotide-exchange factor Mss4: in situ chromosomal 
104 
References 
mapping and expression in pancreatic cancer. Genomics 1997; 46: 389-396. 
Ndisang JF, Wang R. Alterations in heme oxygenase/carbon monoxide system in 
pulmonary arteries in hypertension. Exp Biol Med (Maywood) 2003; 228: 
557-563. 
Nelson DA, Krucher NA, Ludlow JW. High molecular weight protein phosphotase 1 
dephosphorylases the retinoblastoma protein. J Biol Chem 1997; 272: 
4528-4535. 
Olivetti G, Melissari M, Balbi T, Quaini F, Sonnenblick EH, Anversa P. Myocyte 
nuclear and possible cellular hyperplasia contribute to ventricular remodeling 
in the hypertrophic senescent heart in humans. J Am Coll Cardiol 1994; 24: 
140-149. 
Olivetti G, Ricci R, Anversa P. Hyperplasia of myocyte nuclei in long-term cardiac 
hypertrophy in mXs.JClin Invest 1987; 80: 1818-1821. 
Olivetti G, Quaini F, Lagrasta C, Ricci R, Tiberti G, Capasso JM, Anversa P. Myocyte 
cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling 
in anemia-induced cardiac hypertrophy in rats. Am J Pathol 1992; 141: 
227-239. 
Oparil S, Bishop SP, Clubb FJ Jr. Myocardial cell hypertrophy or hyperplasia. 
Hypertension 1984; 6 (6 Pt 2): III38-43. 
Orlic D, Kajstura J，Chimenti S, Jakoniuk I, Anderson SM，Li B, Pickel J, McKay R， 
Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate 
infarcted myocardium. Nature 2001; 410: 701-705. 
Quaini F, Cigola E，Lagrasta C, Saccani G, Quaini E, Rossi C，Olivetti G，Anversa P. 
End-stage cardiac failure in humans is coupled with the induction of 
proliferating cell nuclear antigen and nuclear mitotic division in ventricular 
myocytes. Circ Res 1994; 75: 1050-1063. 
105 
References 
Quaini F, Urbanek K, Beltrami A, Finato N, Beltrami CA, Nadal-Ginard B, Kajstura 
J, Leri A, Anversa P. Chimerism of the transplanted heart. N Engl J Med 2002; 
346: 5-15. 
Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY，Tomatsu S, Fleming RE, 
Sly WS. Association of the transferrin receptor in human placenta with HFE, 
the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 
1997; 94:13198-13202. 
Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circ Res 2002; 90: 
1044-1045. 
Rhee CS, Sen M，Lu D, Wu C, Leoni L，Rubin J, Corr M，Carson DA. Wnt and 
frizzled receptors as potential targets for immunotherapy in head and neck 
squamous cell carcinomas. Oncogene 2002; 21: 6598-6605. 
Rossi MA, Ramos SG, Prado CM. Chronic inhibition of nitric oxide synthase 
induces hypertension and cardiomyocyte mitochondrial and myocardial 
collagen remodelling in the absence of hypertrophy. J Hypertens 2003; 21: 
993-1001. 
Ruiz-Cano MJ, Delgado JF，Jimenez C, Jimenez S，Cea-Calvo L, Sanchez V， 
Escribano P, Gomez MA, Gil-Fraguas L，Saenz de la Calzada C.Successful 
heart transplantation in patients with inherited myopathies associated with 
end-stage cardiomyopathy. Transplant Proc 2003; 35: 1513-1515. 
Salter-Cid L, Brunmark A, Li Y, Leturcq D, Peterson PA, Jackson MR, Yang Y. 
Transferrin receptor is negatively modulated by the hemochromatosis protein 
HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA 
1999; 96: 5434-5439. 
Sherr CJ. Mammalian GI cyclins. Cell 1993; 73: 1059-1065. 
Shu NH. Effect of Radix ophiopogonis and a small dose of magnesium sulfate on 
106 
References 
hemodynamics after myocardial infarction, arrhythmia and the extent of 
myocardial infarction. ZhongXi Yi Jie He Za Zhi 1984; 4: 295-296. 
Simpson P, Savion S. Differentiation of rat myocytes in single cell culture with and 
without proliferating nonmyocardial cells. Cir Res 1982; 50: 101-106. 
Skalli O, Gabbiani G, Babai F, Seemayer TA, Pizzolato G, Schurch W. Intermediate 
filament proteins and actin isoforms as markers for soft tissue tumor 
differentiation and origin. II. Rhabdomyosarcomas. Am J Pathol 1988; 130: 
515-531. 
Snow MH. An autoradiographic study of satellite cell differentiation into 
regenerating myotubes following transplantation of muscles in young rats. Cell 
Tissue Res 1978; 186: 535-540 
Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte 
DNA synthesis. Circ Res 1998; 83: 15-26. 
Stoyanovsky D, Murphy T, Anno PR, Kim Y-M, Salama G. Nitric oxide activates 
skeletal and cardiac ryanodine receptors. Cell Calcium 1997; 21:19-29. 
Strick DJ, Francescutti DM, Zhao Y, Elferink LA. Mammalian suppressor of Sec4 
modulates the inhibitory effect ofRablS during early endocytosis. J Biol Chem 
2002; 277: 32722-32729. 
Tantini B, Pignatti C, Fattori M, Flamigni F, Stefanelli C, Giordano E, Menegazzi M, 
d o C, Caldarera CM. NF-kappaB and ERK cooperate to stimulate DNA 
synthesis by inducing ornithine decarboxylase and nitric oxide synthase in 
cardiomyocytes treated with TNF and LPS. FEES Lett 2002; 512: 75-79. 
Ueda S，Kato S, Matsuoka H, Kimoto M，Okuda S, Morimatsu M，Imaizumi T. 
Regulation of cytokine-induced nitric oxide synthesis by asymmetric 
dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 
2003; 92: 226-233. 
1 0 7 
References 
Vara D, Bicknell KA, Coxon CH, Brooks G. Inhibition of E2F abrogates the 
development of cardiac myocyte hypertrophy. J Biol Chem 2003 Apr 6 [epub 
ahead of print] 
Vulapalli SR, Chen Z, Chua BH, Wang T，Liang CS. Cardioselective overexpression 
of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol 
Heart Circ Physiol 2002; 283: H688-694. 
Wang N, Minatoguchi S, Arai M, Uno Y, Nishida Y, Hashimoto K, Xue-Hai C， 
Fukuda K, Akao S, Takemura G, Fujiwara H. Sheng-Mai-San is protective 
against post-ischemic myocardial dysfunction in rats through its opening of the 
mitochondrial KATP channels. Circ J2002; 66: 763-768. 
Wang N, Minatoguchi S, Uno Y, Arai M, Hashimoto K, Hashimoto Y, Yamaguchi K, 
Fukuda K, Akao S, Fujiwara H. Treatnebt with sheng-mai-san reduces 
myocardial infarct size through activation of protein kinase C and opening of 
mitochondrial KATP channel. Am J Chin Med 2001; 29: 367-375. 
Wang R, Wang ZZ, Wu L. Cdrbon monoxide-induced vasorelaxation and the 
underlying mechanisms. Br J Pharmacol 1997; 121: 927-934. 
Wang YP, Li XY, Song CQ, Hu ZB. Effect of astragaloside IV on T, B lymphocyte 
proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 
2002; 23: 263-266. 
Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 
264-272. 
Xu Y，Hopfner RL, McNeill JR, Gopalakrishnan V. Vasopressin accelerates protein 
synthesis in neonatal rat cardiomyocytes. Mol Cell Biochem 1999; 195: 
183-190. 
Yang-Snyder J, Miller JR, Brown JD, Lai CJ, Moon RT. A frizzled homolog 
functions in a vertebrate Wnt signaling pathway. Curr Biol 1996; 6: 1302-1306. 
108 
References 
Yao M, Qi Y, Bi K, Wang X, Luo X, Che C. A precolumn determination 
high-performance liquid chromatographic method with improved sensitivity 
and specificity for the determination of astragaloside IV in Radix Astragali. J 
Chromatogr Sci 2 0 0 0 ; 3 8 : 3 2 5 - 3 2 8 . 
Yoshida Y, Wang MQ, Shan BE, Yamashita U. Immunomodulating activity of 
Chinese medical herbs and Oldenlandia diffusa in particular. Int J 
Immunopharmacol 1 9 9 7 ; 1 9 : 3 5 9 - 3 7 0 . 
Zammit PS, Heslop L, Hudon V, Rosenblatt JD, Tajbakhsh S, Buckingham ME, 
Beauchamp JR, Partridge TA. Kinetics of myoblast proliferation show that 
resident satellite cells are competent to fully regenerate skeletal muscle fibers. 
Exp Cell Res 2 0 0 2 ; 2 8 1 : 3 9 - 4 9 . 
1 0 9 
Appendix 
One-way ANOVA: Multiple comparisons (Post Hoc tests) 
Descriptives 
d a t a "I 95% Confidence Interval for 
Mean 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound Minimum Maximum 
厂 1418.895135" ******** 8478.009087 15527.4709 10820.00 13576.00 
1 3 ******** 554.0868674 ******** 16750.03858 19502.8947 17486.67 18449.09 
1 ******** 212.1258905 ******** 22121.19674 23175.0966 22406.67 22804.44 
3 3 ******** 2743.727008 ******** 13075.31427 26706.9057 16833.33 22138.00 
4 ******** 4295.299194 ******** 115438.01293 20896.2187 10820.00 22804.44 
Total 12 I • 
Test of Homogeneity of Variances 
DATA 
Levene 
S t a t i s t i c „ _ d f l ^ _ d f 2 
^017 ^ » .032� 
ANOVA 
DATA —I 
二 rlf Mean Square F ^ _ 
Between Groups “ 61052975.� 24.685 .000 
Within Groups 2.0E+07 8 2473327.737 
Total 2.0E+08 L I L L -
Contrast Coefficients 
口T? 4 
Contrast 1 I — 
1 1 I -1 I -1 丨 i J 
Contrast Tests 
— “ Value of • 
广 � c t rnntr;^ c;t Std. Error t df Sig. (2-tailed) 
： ^ 木本氺木木氺木* * * * * * * * * - 4 , 8 9 0 8 . 0 0 1 
DATA Assume equal variances 1 — — 
umA 丨丨mo on..；.!i ******** ******** -4.890 3.219 
Does not assume equal i 
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Post Hoc Tests 
Multiple Comparisons 
Dependent Variable: DATA 
Scheffe 
Mean 
Difference 95% Confidence Inten/al 
(I) FIG 4 P) FIG.4 (I-J) Std. Error Sig. Lower Bound Upper Bound 
2 -6123.7267* ******** .010 -10608.5895 -1638.86387 
3 -10645.407* ******** .000 -15130.2695 -6160.54387 
4 -7888.3700* ******** .002 -12373.2328 -3403.50721 
1 6123.72667* ******** .010 1638.863872 10608.5895 
3 -4521.6800* ******** .048 -9006.54279 -36.8172056 
4 -1764.6433 ******** .616 -6249.50613 2720.21946 
1 10645.4067* ******** .000 6160.543872 15130.2695 
2 4521.68000* ******** .048 36.81720556 9006.54279 
4 2757.03667 ******** .278 -1727.82613 7241.89946 
i 7888.37000* ******** .002 3403.507206 12373.2328 
2 1764.64333 ******** .616 -2720.21946 6249.50613 
3 -2757.0367 ******** .278 -7241.89946 1727.82613 




Subset for alpha = .05 
FIG.4 N 1 2 3 
1 2 ******** 
2 2 氺本氺氺本木氺木 
4 2 本本本本木氺氺本 本 木 本 本 木 本 * * 
— ^ * * 本 * * * * * 
Sig. 1.000 .616 .278 
Means for groups in homogeneous subsets are displayed, 
a. Uses Harmonic Mean Sample Size = 3.000. 
Appendix 1: Example of the statistical result of ^H-thymidine incorporation of day 1 
primary rat cardiomyocytes after treating with different concentration of HQ for 3 
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